

## REMARKS

Claims 46-89 are pending.

Applicants have elected the subject matter of Group I, claims 46-67.

The claims have been amended to incorporate the sequence identifiers, where appropriate. Further, the claims have been renumbered to reflect the examiner's marked-up copy of the claims that accompanied the Office Action.

The present specification and claims have been amended to include sequence identifiers. A marked-up copy of the specification and a clean, substitute specification are being provided herewith.

In addition to complying with the sequence requirements, the specification has been amended to eliminate underlining of the section headings, relocate the description of the drawings, and to conform the order of the specification to preferred US practice. No new matter is added by this amendment.

A marked-up copy of the amended specification is being supplied herewith, together with a clean copy of the specification, in order to clearly and efficiently identify all the amendments.

The application has been amended to place it in compliance with the sequence rules. A substitute Sequence Listing was filed via the Electronic Filing System on October 23, 2003. A copy of the Acknowledgement Receipt is enclosed.


This filing via the EFS obviates any further hard copy or electronic copy being supplied with this paper. Applicants request withdrawal of the objections to the specification.

No new matter is added by this amendment.

The Director of the U. S. Patent and Trademark Office is hereby authorized to charge any deficiency in any fees due with the filing of this paper to Deposit Account No. 08-3040.

Respectfully submitted,  
HOWSON AND HOWSON  
Attorneys for the Applicants

By

  
Cathy A. Rodroff  
Registration No. 33,980  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
Phone: (215) 540-9210  
Fax: (215) 540-5818



**"MARKED-UP COPY OF SPECIFICATION"**

**PROTEASE SUSCEPTIBILITY II**

**BACKGROUND OF THE INVENTION**

**TECHNICAL FIELD**

5           The present invention relates to: manipulation of the amino acid sequence of tropoelastin, particularly human tropoelastin, to modify its protease susceptibility; to tropoelastin derivatives having modified protease susceptibility; to peptidomimetic molecules which contain  
10 amino acid sequences which correspond to or incorporate the protease susceptible sequences of tropoelastin; and to uses of the tropoelastin derivatives and peptidomimetic molecules.

          The invention also relates to nucleic acid molecules  
15 and genetic constructs encoding the amino acid sequences of the derivatives and peptidomimetic molecules of the invention.

**BACKGROUND ART**

          The insoluble cross-linked elastin molecule is highly  
20 resistant to proteolytic degradation by many proteases. However, tropoelastin, the soluble precursor of elastin, is far more vulnerable to proteolysis. Attempts at purifying tropoelastin from tissues usually result in a collection of degraded products. This degradation can be decreased by  
25 using traditional inhibitors of serine proteases (Franzblau et al., 1989; Rucker, 1982, Rich and Foster, 1984; Sandberg and Wolt, 1982). Specific degradation has also been noted in cell culture of smooth muscle cells which was attributed to metalloproteinases (Hayashi et al., 1995). Even highly  
30 purified tropoelastin can degrade into discrete bands on prolonged storage. This observation has led to a hypothesis that mammalian tropoelastin is occasionally co-purified with an intrinsic protease which will promote its gradual breakdown (Mecham et al., 1976; Mecham et al.,  
35 1977; Mecham and Foster, 1977). Experiments have shown

that mammalian serum contains proteases which are capable of degrading tropoelastin (Romero *et al.*, 1986). Thus, any newly-synthesized unprotected tropoelastin exposed to blood, such as in a blood vessel wall, would be rapidly degraded. Serum has also been shown to induce elastase activity in smooth muscle cells leading to degradation of elastin (Kobayashi *et al.*, 1994). Elastin peptides are known to be chemotactic and this could be a role of tropoelastin proteolysis *in vivo* (Grosso and Scott, 1993; Bisaccia *et al.*, 1994). However, proteolysis could also result in inadequate or faulty elastin fiber repair at the site of injury. Serine protease inhibitors have been shown to reduce the degradation of tropoelastin caused by serum (Romero, *et al.*, 1986). These experiments suggested that kallikrein was a candidate serum protease. Other experiments (McGowan *et al.*, 1996) proposed that plasmin was a major protease involved. Thrombin has been used to digest heterogeneous porcine tropoelastin *in vitro* (Torres *et al.*, 1976). However, none of these studies has provided indication of where the tropoelastin molecule is cut by proteases.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a schematic diagram illustrating the relative positions of protease sites identified by N-terminal sequencing for serum, kallikrein and thrombin. Major sites are indicated with a solid bar while minor sites are indicated with a stippled bar. Since most plasmin fragments contained the same N-terminal sequence the site of cleavage could not be identified unambiguously. The trypsin fragments identified similarly all contained the same N-terminal sequence. Therefore, the likely regions of cleavage for plasmin and trypsin are not shown.

Figure 2 shows the nucleotide sequence and amino acid sequence of SHEL. The positions of the protease

recognition sites are underlined. The nucleic acid sequence is show in SEQ ID NO:3 and the amino acid of SHEL is shown in SEQ ID NO:4.

5 Figure 3 shows the amino acid sequence of SHELδ26A (bottom line) compared to the amino acid sequence of SHEL [aa 3 - 733 of SEQ ID NO: 4]. The amino acid sequence of SHELδ26A is shown in SEQ ID NO:5.

10 Figure 4 shows the nucleotide sequence and amino acid sequence of SHELδmod. The nucleic acid sequences are nucleotides (nt) 1-1983 of SEQ ID NO:2. The amino acid sequence of SHELδmod is shown in SEQ ID NO:6.

15 Figure 5 shows 10% SDS PAGE analysis of SHEL with serum after incubation for 1,2 ,3 or 18 hours (Lanes 1 to 4). Lanes 5 and 6: peptide fragments produced by serum digestion of SHEL and SHELδ26A respectively, purified by butanol solubilisation. Approximate sizes of fragments produced are shown in kDa. Size markers are shown in kDa.

20 Figure 6 shows 8% SDS-PAGE analysis of the effect of protease inhibitors on serum degradation of SHEL. Lanes 1, 3, 5, 7 and 9: SHEL incubated with serum; lane 2: SHEL incubated with serum and 0.5mM Pefabloc SC; lane 4: SHEL incubated with serum and 5mM PMSF; lane 6: SHEL incubated with serum and EDTA; lane 8: SHEL incubated with serum and 50 mMPefabloc PK; and lane 10: SHEL incubated with serum and 1 unit Hirudin.

25 Figure 7 shows 8% SDS-PAGE analysis of the effect of thrombin on SHEL and SHELδ26A. Increasing amounts of thrombin: lane 1 (0.01 units); lane 2 (0.05 units); lane 3 (0.10 units); lane 4 (0.15 units); lane 5 (0.20 units) and lane 6 (0.25 units) were added to SHEL. Lanes 7 and 8: effect of thrombin (1U) on degradation of SHEL and SHELδ26A respectively. Fragment sizes are estimated in kDa. Size markers are shown in kDa.

Figure 8 shows 8% SDS-PAGE analysis of the effect of

kallikrein on SHEL and SHELδ26A. Increasing concentrations of kallikrein: lane 1:  $3.0 \times 10^{-4}$ ; lane 2:  $6.0 \times 10^{-4}$ ; lane 3:  $1.5 \times 10^{-3}$  and lane 4:  $3.0 \times 10^{-3}$  were added to SHEL. Lanes 5 and 6: effect of kallikrein ( $6 \times 10^{-4}$ U) on degradation of SHEL and SHELδ26A respectively. Fragment sizes and size markers are shown in kDa.

Figure 9 shows 10% SDS-PAGE analysis of the effect of bovine trypsin on SHEL and SHELδ26A. Increasing concentrations of bovine trypsin: lane 1:  $5 \times 10^{-4}$ ; lane 2:  $1 \times 10^{-3}$ ; lane 3:  $2 \times 10^{-3}$  and lane 4:  $4 \times 10^{-3}$  were added to SHEL. Lanes 5 and 6: effect of bovine trypsin ( $2 \times 10^{-3}$ U) on SHEL and SHELδ26A respectively. Fragment sizes and size markers are shown in kDa.

Figure 10 shows 10% SDS-PAGE analysis of the effect of plasmin on SHEL and SHELδ26A. Increasing concentrations of plasmin: lane 1:  $3.7 \times 10^{-7}$ ; lane 2:  $7.4 \times 10^{-7}$ ; lane 3:  $3.7 \times 10^{-6}$ ; lane 4:  $7.4 \times 10^{-6}$ ; lane 5:  $3.7 \times 10^{-5}$ ; lane 6:  $7.4 \times 10^{-5}$  were added to SHEL. Lanes 7 and 8: effect of plasmin ( $7.4 \times 10^{-5}$ U) on SHEL and SHELδ26A respectively. Fragment sizes and size markers are shown in kDa.

Figure 11 shows 10% SDS-PAGE analysis of the effect of human leukocyte elastase (HLE) on SHEL and SHELδ26A. Increasing concentrations of HLE: lane 1:  $1.6 \times 10^{-4}$ ; lane 2:  $3.2 \times 10^{-4}$ ; lane 3:  $8.0 \times 10^{-4}$ ; lane 4:  $1.6 \times 10^{-3}$ ; lane 5:  $3.2 \times 10^{-3}$  were added to SHEL. Lanes 6 and 7: effect of HLE ( $1.6 \times 10^{-3}$ U) on SHEL and SHELδ26A respectively. Fragment sizes and size markers are shown in kDa.

Figure 12 shows 10% SDS-PAGE analysis of the effect of S-GAL and SPS-peptide on degradation of SHEL with A: serum, 1/2 dilution 20min; B: trypsin 20min; C: plasmin  $1.5 \times 10^{-5}$ U 20min; D: kallikrein  $15 \times 10^{-4}$ U 40min; E: thrombin 0.1U 20min and F: HLE 70min. Thrombin and kallikrein were used with a 100:1 ratio. Gels were scanned by densitometry and the relative amount of each full-length SHEL band is shown in a

histogram.

Figure 13 shows SDS-PAGE analysis of the effect of coacervation on the degradation of SHEL by proteases. SHEL was incubated in the presence (+) or absence (-) of a concentration of NaCl conducive to coacervation of SHEL at 37°C with A: kallikrein; B: thrombin; C: HLE; D: trypsin; E: plasmin and F: serum; or in the presence (+) or absence (-) of a concentration of NaCl conducive to coacervation of SHEL at 16°C with G: kallikrein; H: thrombin; I: HLE; J: trypsin; K: plasmin and L: serum.

Figure 14 shows 8% SDS-PAGE gel of the effect of thrombin cleavage of soluble cell lysate containing GST-SHEL. Increasing amounts of thrombin: lane 1: 0.001 unit; lane 2: 0.005 unit; lane 3: 0.010 unit; lane 4: 0.050 unit; lane 5: 0.100 unit; lane 6: 0.500 unit and lane 7: 1.000 unit were added to soluble cell lysate.

Figure 15 shows the construction scheme for pSHELF $\delta$ 26A. pSHELF and the aberrant pSHELF $\delta$ mod were both digested with SpeI and BssHII. BssHII cuts both plasmids twice and SpeI once resulting in three fragments. The 5424 and 946bp fragments from pSHELF and the small 338bp fragment from pSHELF $\delta$ mod were purified from agarose gels. The 5424bp fragment was CIP treated to reduce recircularisation and the three fragments ligated overnight at 16°C using DNA ligase. The final product pSHELF $\delta$ 26A contained the desired deletion of exon 26A from the SHEL gene with no other mutations.

Figure 16 shows a zymogram analysis of SHEL digested with serum (Lane 1), serum with Pefabloc SC (Lane 2) or kallikrein (Lane 3).

Figure 17 shows a zymogram analysis of gelatin digested with serum in the presence of Ca<sup>2+</sup> (Lane 1), Zn<sup>2+</sup> (Lane 2), Ca<sup>2+</sup> and Zn<sup>2+</sup> (Lane 3) and Ca<sup>2+</sup>, Zn<sup>2+</sup> and EDTA (Lane 4).

Figure 18 shows a zymogram analysis of gelatin

digested with AMPA activated gelatinase A (Lane 1), unactivated gelatinase A (Lane 2) and serum (Lane 3).

Figure 19 shows protease digestion of SHEL in solution. Lane 1, standards. Lane 2, SHEL. Lane 3, SHEL plus serum. Lane 4, SHEL plus 72kDa gelatinase. Lane 5, SHEL plus 92kDa gelatinase. Lanes 6 and 7, serum plus APMA (1hr incubation), Lanes 8 and 9, serum plus APMA (overnight incubation).

Figure 20 shows human serum kallikrein digestion of SHEL in sodium phosphate buffer, pH7.8 in the presence and absence of urea. Lane 1, standards, Lane 2, SHEL (not incubated), Lane 3, SHEL incubated with buffer (no kallikrein), Lane 4, SHEL plus kallikrein, Lane 5, SHEL plus urea in buffer (no kallikrein), Lane 6, SHEL plus kallikrein in 0.3M urea, Lane 7, SHEL plus kallikrein in 1M urea.

## DETAILED DESCRIPTION OF THE INVENTION

### DESCRIPTION OF THE INVENTION

In purifying a defined species of recombinant human tropoelastin (Martin *et al.*, 1995) from its fusion partner the present inventor observed limited and reproducible cleavage of the tropoelastin, by thrombin. The pattern of degradation as seen on SDS-polyacrylamide gels was similar to that seen by others during purification and storage (Mecham *et al.*, 1977). The present inventor recognised the possibility that this may be because certain portions of tropoelastin are more susceptible to protease action or are more readily available to proteases because of tropoelastin's conformation in solution. A comparison of the sizes of the protease cleavage products with the amino acid sequence of tropoelastin and the consensus cleavage sites for the proteases being examined revealed that of the many sites in the tropoelastin amino acid sequence which

are homologous to consensus sequences for particular proteases, few were readily digested by proteases. By mapping the sites at which digestion was taking place, susceptible regions were identified thus providing the first precise mapping of protease cleavage sites within any tropoelastin.

From the determination of these susceptible regions, tropoelastin amino acid sequences in these susceptible regions can be modified thus providing reduced tropoelastin derivatives which have a reduced or eliminated protease susceptibility under particular conditions, as compared with the protease susceptibility of tropoelastin under the same conditions.

In the specification and claims, "reduced tropoelastin derivative" means a molecule having a modification of an amino acid sequence in a susceptible region of tropoelastin, which molecule is folded in a functional conformation. "Functional conformation" is defined below. The modification of the amino acid sequence in the susceptible region causes reduced or eliminated protease susceptibility. Reduced tropoelastin derivatives may correspond to full length tropoelastin molecules, single domains of tropoelastin which are encoded by specific exons of the tropoelastin gene or peptides which are encoded by all or part of two neighbouring exons of the tropoelastin gene.

Reduced tropoelastin derivatives may be produced by mutation events including for example, single point mutation in a nucleotide sequence which cause a residue substitution in an amino acid sequence in a susceptible region, or mutation events in a nucleotide sequence which cause an amino acid insertion or deletion in an amino acid sequence in a susceptible region. Reduced tropoelastin derivatives can also be produced by mutation of tropoelastin sequences, in regions of the tropoelastin



molecule which are susceptible to protease digestion, and further mutation in other regions of tropoelastin. The further mutations may or may not alter the susceptibility of the reduced tropoelastin derivative to proteases.

- 5 Reduced tropoelastin derivatives which contain these mutations may be produced synthetically.

Reduced tropoelastin derivatives may alternatively be produced by chemical modification of amino acid side chains in the derivative which chemically modifies a susceptible  
10 region.

Reduced tropoelastin derivatives may in another alternative be produced by protease digestion. Thus according to the invention, a protease digestion product of tropoelastin, which, as a result of digestion, has lost an  
15 amino acid sequence which is in a susceptible region, is a reduced tropoelastin derivative.

Reduced tropoelastin derivatives can also be produced by modification of tropoelastin variant amino acid sequences, in regions of the tropoelastin molecule which  
20 are susceptible to protease digestion.

In the specification and claims, "variants of tropoelastin" or "tropoelastin variants" means molecules which retain one or more properties of the corresponding tropoelastin molecule, for example, elastin-like properties  
25 or macro-molecular binding properties. Elastin-like properties include the phenomenon of recoil after molecular distention and the ability to undergo cross -linking and coacervation. Macro-molecular binding properties include the ability to interact with other macro-molecules, for  
30 example glycosylaminoglycans. Tropoelastin variants have an amino acid sequence which is homologous to all or part of the amino acid sequence of a tropoelastin splice form. For the purposes of this description, "homology" between the amino acid sequence of a particular variant and all or part  
35 of a tropoelastin splice form connotes a likeness short of

identity, indicative of a derivation of one sequence from the other. In particular, an amino acid sequence is homologous to all or part of a tropoelastin sequence if the alignment of that amino acid sequence with the relevant  
5 tropoelastin sequence reveals an identity of about 65% over any 20 amino acid stretch or over any repetitive element of the molecules shorter than 20 amino acids in length. Such a sequence comparison can be performed via known algorithms such as that of Lipman and Pearson (1985). Tropoelastin  
10 variants may contain amino acid sequence differences as compared with tropoelastin, at a region susceptible to proteolysis, which differences do not alter the protease susceptibility of the tropoelastin variant as compared with tropoelastin. An example of such an amino acid sequence  
15 difference at a susceptible region in a tropoelastin variant may be a conservative amino acid substitution.

Thus reduced tropoelastin derivatives may be produced by mutation of a tropoelastin variant amino acid sequence, including for example, single point mutations in a  
20 nucleotide sequence which causes a residue substitution in an amino acid sequence in a susceptible region of tropoelastin. The reduced tropoelastin derivatives may also be produced by mutation of a tropoelastin variant amino acid sequence, including for example mutation events  
25 in a nucleotide sequence which cause an amino acid insertion or deletion in an amino acid sequence in a susceptible region of tropoelastin. Reduced tropoelastin derivatives can be produced by mutation of tropoelastin variant sequences, in regions of the tropoelastin molecule  
30 which are susceptible to protease digestion, and further mutation in other regions of the reduced tropoelastin variant. The further mutations may or may not alter the susceptibility of the reduced tropoelastin derivative to proteases. Reduced tropoelastin derivatives which are  
35 produced by the mutation of a tropoelastin variant may be

produced synthetically.

Alternatively, reduced tropoelastin derivatives may be produced by chemical modification of amino acid side chains in the derivative which chemically modifies a susceptible region.

Alternatively, reduced tropoelastin derivatives may also be produced by protease digestion of a tropoelastin variant. Thus according to the invention, a protease digestion product of a tropoelastin variant, which, as a result of digestion, has lost an amino acid sequence in a susceptible region, is a reduced tropoelastin derivative.

It is known that tropoelastin genes in nature are expressed as multiple transcripts which are distinguished by alternative splicing of the mRNA as described in, for instance, Indik *et al* (1990); Oliver *et al* (1987); Heim *et al* (1991); Raju *et al* (1987) and Yeh *et al* (1987). The methods of the present invention can also be applied to the different splice forms of tropoelastin. The skilled addressee will readily recognise that in applying the methods of the invention to various splice forms of tropoelastin, account must be taken of the presence or absence of the identified cleavage sites in the amino acid sequence of the particular splice form in question.

Human tropoelastins are described by Indik *et al* (1990) and Tassabehji *et al* (1997). Bressan *et al* (1987) describe the amino acid sequence of chick tropoelastin, while Raju *et al* (1987) describe the amino acid sequence of bovine tropoelastin and Pierce *et al* (1992) describe the amino acid sequence of rat tropoelastin. Again taking account of variations in amino acid sequence and the existence of different splice forms, the skilled addressee will recognise that the methods of the invention can be applied to tropoelastins from other species.

In a first aspect the present invention provides a method for reducing or eliminating the susceptibility of a

tropoelastin or tropoelastin variant amino acid sequence to proteolysis which method comprises mutating at least one sub-sequence in the tropoelastin or tropoelastin variant amino acid sequence, to reduce or eliminate the susceptibility of the tropoelastin or tropoelastin variant to proteolysis.

In the specification and claims, a "sub-sequence" means a sequence which is capable of being cleaved (or in other words, digested) by a protease when tropoelastin or a tropoelastin variant is folded in a functional conformation. A "functional conformation" is the conformation which imparts the elastin -like properties and macro -molecular binding properties to tropoelastin. The sub-sequences correspond to the amino acid sequences in the regions of tropoelastin which are susceptible to proteolysis.

Typically, the mutation involves altering at least one or two residues in the sub-sequence so as to reduce or eliminate susceptibility. More preferably, at least one sub-sequence is mutated. More preferably the tropoelastin is human tropoelastin.

It will be recognised that mutation to remove one or more sub-sequences which are capable of being digested by a serine protease is of particular benefit when the tropoelastin or tropoelastin variant is to be exposed to serum since the major proteolytic activity of serum for tropoelastin is serine protease activity.

In one embodiment of the first aspect of the invention, the sub-sequence is capable of being digested by a serine protease and has an amino acid sequence including the sequence RAAAG [aa 1-5 of SEQ ID No: 9], or an amino acid sequence selected from the group of sequences shown in SEQ ID NOS: 17 to 44. When the sub-sequence is an amino acid sequence selected from the group of sequences shown in SEQ ID NOS: 17 to 44, or has an amino acid sequence

including RAAAG [aa 1-5 of SEQ ID No: 9], the sub-sequence is preferably mutated by replacing arginine in the sub-sequence with alanine. Preferably, the sub-sequence is capable of being digested by thrombin and has an amino acid sequence shown in SEQ ID NOS: 8 or 9. Preferably the sub-sequence is capable of being digested by plasmin and has an amino acid sequence shown in SEQ ID NOS: 11 or 12. More preferably, the sub-sequence is capable of being digested by kallikrein. Yet more preferably, the sub-sequence is capable of being digested by kallikrein and has an amino acid sequence shown in any one of SEQ ID NOS: 9 or 10.

The present inventor has noted that cleavage of SHEL and SHEL $\delta$ 26A with metalloproteinases leads to reproducible patterns with apparently preferred cleavage sites, evidenced using methods similar to those described here. Examples of metalloproteinases include gelatinases A and B, the 72kD and 92kD proteases, and matrix metallo elastase. Significantly SDS-PAGE indicates that cleavage is, at least in some obvious instances, different to the recognition sequences seen with serine proteases as described in Table 1. Using the 92 kDa metalloproteinase, a characteristic banding pattern was obtained with clear evidence of preferred, more intense bands. For example, using methods described herein for the serine proteases, N-terminal sequencing of an approximately 10 kDa band derived from SHEL revealed the sequence: LAAAKAAKYGAA [aa 594-604 of SEQ ID NO:4]. Its location in SHEL is illustrated in Figure 2. Thus a preferred recognition site resides between A and L, which is N-terminally upstream of the identified sequence of this fragment. It will be recognised that mutation to the tropoelastin or a tropoelastin variant sequence to remove one or more sub-sequences which are digested by metalloproteinases is of particular benefit when the tropoelastin or tropoelastin variant is to be exposed to, for example, wound sites, locations of tissue

damage and remodelling which can expose the tropoelastin or tropoelastin variant to metalloproteinases.

In another embodiment of the first aspect of the invention, the sub-sequence is capable of being digested by a metalloproteinase and has an amino acid sequence including the sequence ALAAA [aa 1-5 of SEQ ID NO:13], or an amino acid sequence selected from the group of sequences shown in SEQ ID NOS: 45 to 70. Preferably, the sub-sequence is capable of being digested by gelatinase A or B. Preferably the sub-sequence has the amino acid sequence shown in SEQ ID NO: 13. When the sub-sequence is an amino acid sequence selected from the group of sequences shown in SEQ ID NOS: 45 to 70, or has an amino acid sequence including ALAAA [aa 1-5 of SEQ ID NO:13], the sub-sequence is preferably mutated by replacing alanine at any position in the sub-sequence with another amino acid residue. More preferably, the alanine N-terminal to the leucine is mutated by replacing that alanine with another amino acid residue.

In a second aspect the present invention provides a reduced tropoelastin derivative exhibiting reduced or eliminated susceptibility to proteolysis in comparison with a corresponding tropoelastin or a corresponding tropoelastin variant, the reduced tropoelastin derivative characterised in that a sub-sequence of the corresponding tropoelastin or corresponding tropoelastin variant amino acid sequence is mutated in the reduced tropoelastin derivative to eliminate or reduce the susceptibility of the reduced tropoelastin derivative to proteolysis.

Typically at least one or two residues are mutated in the sub-sequence. More preferably, at least one sub-sequence is mutated. More preferably the tropoelastin is human tropoelastin.

In one embodiment of the second aspect of the invention, the mutated sub-sequence has reduced or

eliminated susceptibility to digestion by a serine protease. Preferably the mutated sub-sequence includes the sequence RAAAG [aa 1-5 of SEQ ID NO:9], or is a sequence selected from the group of sequences shown in SEQ ID NOS: 5 17 to 44, provided that arginine in the sequence is replaced with alanine. Preferably the mutated sub-sequence has reduced or eliminated susceptibility to digestion by thrombin, and the mutated sub-sequence has the sequence shown in SEQ ID NOS: 8 or 9, provided that at least one 10 amino acid residue in the sequence is mutated. Preferably the mutated sub-sequence has reduced or eliminated susceptibility to digestion by plasmin, and the mutated sub-sequence has the sequence shown in SEQ ID NOS: 11 or 12, provided that at least one amino acid residue in the 15 sequence is mutated. More preferably, the mutated sub-sequence has reduced or eliminated susceptibility to digestion by kallikrein. Yet more preferably, the mutated sub-sequence has reduced or eliminated susceptibility to digestion by kallikrein and the mutated sub-sequence has 20 the sequence shown in SEQ ID NOS: 9 or 10, provided that at least one amino acid residue in the sequence is mutated.

In another embodiment of the second aspect of the invention, the mutated sub-sequence has reduced or eliminated susceptibility to digestion by a 25 metalloproteinase. Preferably the mutated sequence includes the sequence ALAAA [aa 1-5 of SEQ ID NO:13], or is a sequence selected from the group of sequences shown in SEQ ID NOS: 45 to 70, provided that alanine at any position in the sequence is replaced with any amino acid residue 30 except alanine. More preferably, the mutated sub-sequence has reduced or eliminated susceptibility to digestion by gelatinase A or B. More preferably, the mutated sub-sequence has reduced or eliminated susceptibility to digestion by gelatinase B and the mutated sub-sequence has 35 the sequence shown in SEQ ID NO: 13, provided that at least

one amino acid residue in the sequence is mutated. More preferably, the alanine N-terminal to the leucine is mutated by replacing that alanine with another amino acid residue.

5       Reduced tropoelastin derivatives of the second aspect with mutations appropriate to their use environment can beneficially be used *in vivo* at sites where there is a risk of protease attack on tropoelastin or a variant of tropoelastin, such as in the presence of serum or wound  
10       exudate. For instance, the therapeutic use of cross-linked tropoelastin or a cross-linked tropoelastin variant in blood vessel walls would benefit since serum-induced degradation could be reduced. Further, certain  
15       modifications should reduce the need to use protease inhibitors during purification of the reduced tropoelastin derivative and result in greater amounts of full-length material if one or more susceptible regions are modified to minimise attack by endogenous host proteases.

      In a third aspect the present invention provides a  
20       method of protecting a tropoelastin or a tropoelastin variant from degradation by serum or a protease selected from the group consisting of kallikrein, thrombin, trypsin and related serine proteases, including elastase, which  
25       method comprises mutating at least one sub-sequence in the tropoelastin or tropoelastin variant amino acid sequence to reduce or eliminate the susceptibility of the tropoelastin or tropoelastin variant to proteolysis. Preferably the tropoelastin is human tropoelastin. Preferably the protease is kallikrein.

30       In a fourth aspect the present invention provides a method of protecting a tropoelastin or a tropoelastin variant from degradation by proteolytic attack, which  
35       method comprises mutating at least one sub-sequence in the tropoelastin or tropoelastin variant amino acid sequence to reduce or eliminate the susceptibility of the tropoelastin



or tropoelastin variant to proteolysis. In one embodiment the sub-sequence is digested by a metalloproteinase.

As described above, amino acid sequences of non-human tropoelastins have been determined, including the amino acid sequences of chick tropoelastin, bovine tropoelastin and rat tropoelastin (Bressan et al. 1987, Raju et al. 1987, Pierce et al. 1992). A comparison of these non-human tropoelastin amino acid sequences with tropoelastin reveals that particular regions of tropoelastin which are susceptible to proteolysis as identified in the present invention are conserved in these non-human tropoelastins. Therefore it is likely that these particular regions in the non-human tropoelastins will be susceptible to proteolysis.

The analysis of the sub-sequences described in Table 1 with non human tropoelastin or elastin sequences with the 'nr' database using 'tblastn' at the NCBI Blast facility (<http://www.ncbi.nlm.nih.gov/BLAST>) shows the following:

(i) human tropoelastin:

20 554 VPTGAGVKPKAPGVGGAF 607 [aa 145-162 of SEQ ID NO:4]

bovine tropoelastin, exon 14

373 VPTGAGVKPKAPGGGGAF 426 [SEQ ID NO: 75]

25 mouse tropoelastin mRNA complete cds

694 VPTGTGVKAKAPGGGGAF 747 [SEQ ID NO: 76]

bovine elastin a mRNA complete cds

545 VPTGAGVKPKAQVGAGAF 598 [SEQ ID NO: 77]

30

bovine elastin b mRNA complete cds

545 VPTGAGVKPKAQVGAGAF 598 [SEQ ID NO: 77]

bovine elastin c mRNA complete cds

5 545 VPTGAGVKPKAQVGAGAF 598 [SEQ ID NO: 77]

rat tropoelastin mRNA 3' end

646 VPTGTGVKAKVPGGGG 693 [SEQ ID NO: 78]

10 chicken tropoelastin mRNA complete cds

572 VPTGTGIKAKGPGAG 616 [SEQ ID NO: 79]

(ii) human tropoelastin:

1664 KVAAKAQLRAAAGLGAG 1714 [aa 509-525 of SEQ ID NO:4]

15

rat tropoelastin mRNA 3' end

1837 KAAAKAQYRAAAGLGAG 1887 [SEQ ID NO: 80]

mouse tropoelastin mRNA complete cds

20 1795 KAAAKAQYRAAAGLGAG 1845 [SEQ ID NO: 80]

bovine elastin a mRNA complete cds

1649 KAAAKAQFRAAAGLPAG 1699 [SEQ ID NO: 81]

25 bovine elastin b mRNA complete cds

1607 KAAAKAQFRAAAGLPAG 1657 [SEQ ID NO: 81]

bovine elastin c mRNA complete cds

1547 KAAAKAQFRAAAGLPAG 1597 [SEQ ID NO: 81]

30

which demonstrates that the sub-sequences identified in Table 1 are highly homologous with non human tropoelastin or elastin sequences, supporting the proposition that taking account of sequence differences the methods of the invention can be applied to different tropoelastin species.

35

This analysis also demonstrates a consensus sequence:  
AKAAAKAQN<sub>0</sub>R/AAAGLN<sub>1</sub>AGN<sub>2</sub>P [SEQ ID NO: 82]

wherein N<sub>0</sub> is an aromatic or hydrophobic residue;

N<sub>1</sub> is P or G; and

5 N<sub>2</sub> is a hydrophobic residue

for the site in tropoelastin which is cleaved by kallikrein and thrombin. An amino acid sequence which is within the definition of this consensus sequence may be mutated in accordance with the methods of the invention to provide the  
10 derivatives of the invention which have, for example, reduced or eliminated susceptibility to proteolysis.

In the human tropoelastin splice form described in more detail herein and shown in SEQ ID NO:4, the cleavage in serum occurs between residues 515 and 516; 564 and 565;  
15 441 and 442; 503 and 504. Thus for this splice form the alteration to the sequence to influence serine protease susceptibility preferably involves modification of at least one of residues 515, 516, 564, 565, 441, 442, 503, 504, 564 and 565.

20 Alterations to reduce susceptibility to protease attack can be considered to involve removal or modification of the recognition site. An example of this modification is the replacement of lysine or arginine by an amino acid residue that is not positively charged. An example of this  
25 approach is the use of leucine to replace arginine in the sequence R/AAAGLG [SEQ ID NO:9] of Table 1 using common methods of mutagenesis such as those available commercially in kit form.

Reduced tropoelastin derivatives of the invention  
30 include:

- SHELδ26a (shown in Figure 3; SEQ ID NO: 5);
- SHELδmod (shown in Figure 4; SEQ ID NO:6);
- sequences shown in SEQ ID NOS: 71 to 74.

As the inventor has determined the regions of  
35 tropoelastin which are susceptible to proteolysis,

tropoelastin can be modified by inserting a sequence which corresponds to an amino acid sequence in a susceptible region of tropoelastin, into the tropoelastin amino acid sequence, thus providing an enhanced tropoelastin

5 derivative which has enhanced protease susceptibility under particular conditions as compared with the protease susceptibility of tropoelastin under the same conditions.

Thus, in the specification and claims, "enhanced tropoelastin derivative" means a molecule produced by  
10 inserting a sequence which corresponds to an amino acid sequence in a susceptible region of tropoelastin, into the tropoelastin amino acid sequence, which molecule is folded in a functional conformation. The insertion of the amino acid sequence which corresponds to the amino acid sequence  
15 of a susceptible region causes enhanced protease susceptibility. Enhanced tropoelastin derivatives may correspond to full length tropoelastin molecules, single domains of tropoelastin which are encoded by specific exons of the tropoelastin gene or peptides which are encoded by  
20 all or part of two neighbouring exons of the tropoelastin gene.

Insertion of the amino acid sequence into tropoelastin, may occur by, for example, splicing a peptide which has an amino acid sequence which corresponds to a  
25 susceptible region in tropoelastin, into tropoelastin. Thus, enhanced tropoelastin derivatives may be produced by mutation events including a mutation in a nucleotide sequence which causes an insertion of a peptide in the tropoelastin amino acid sequence wherein the inserted  
30 peptide corresponds to an amino acid sequence in a susceptible region of tropoelastin.

Alternatively, insertion of the amino acid sequence into tropoelastin may occur by modifying an amino acid sequence in a region of tropoelastin, by residue insertion,  
35 substitution or deletion, so as to generate an amino acid

sequence in that region of tropoelastin which is the same as an amino acid sequence in a susceptible region of tropoelastin. Thus, enhanced tropoelastin derivatives may be produced by mutation events including a mutation in a nucleotide sequence which causes residue insertion, substitution or deletion in a region of tropoelastin, wherein the mutation events produce at the region, an amino acid sequence which corresponds to a susceptible region of tropoelastin.

Enhanced tropoelastin derivatives which have an inserted amino acid sequence in accordance with either of the above, may be mutated further by residue insertion, substitution or deletion, or further amino acid sequence insertion. The further mutations may or may not alter the susceptibility of the enhanced tropoelastin derivative to proteases. Enhanced tropoelastin derivatives which contain these mutations may be produced synthetically.

Enhanced tropoelastin derivatives can be produced by modification of tropoelastin variant amino acid sequences, in regions of tropoelastin which are susceptible to protease digestion.

Thus, enhanced tropoelastin derivatives may be produced by mutation of a tropoelastin variant amino acid sequence including a mutation in a nucleotide sequence which causes an insertion of a peptide in the tropoelastin variant amino acid sequence wherein the inserted peptide corresponds to an amino acid sequence in a susceptible region of tropoelastin.

Alternatively, enhanced tropoelastin derivatives may be produced by mutation of a tropoelastin variant amino acid sequence including a mutation in a nucleotide sequence which causes residue insertion, substitution or deletion in a region of a tropoelastin variant amino acid sequence, wherein the mutation events produce at the region, an amino acid sequence which corresponds to a susceptible region of

tropoelastin.

Enhanced tropoelastin derivatives which have an inserted amino acid sequence in accordance with either of the above, may be mutated further by residue insertion, substitution or deletion, or further amino acid sequence insertion in the tropoelastin variant amino acid sequence. The further mutations may or may not alter the susceptibility of the enhanced tropoelastin derivative to proteases. Enhanced tropoelastin derivatives which contain these mutations may be produced synthetically or by recombinant methods.

As described above, the tropoelastin amino acid sequence is known to be translated in various mRNA splice forms in humans and non-human animals. Further the comparison of human and non-human tropoelastin amino acid sequences reveals amino acid homology between tropoelastin amino acid sequences. Thus, these various isoforms of human and non-human tropoelastin and the mRNA splice forms encoding them can be modified to provide the enhanced tropoelastin derivatives of the invention.

In a fifth aspect the invention provides a method for enhancing the susceptibility of a tropoelastin or tropoelastin variant amino acid sequence to proteolysis, which method comprises inserting a sub-sequence into a tropoelastin or tropoelastin variant amino acid sequence to enhance the susceptibility of the tropoelastin or tropoelastin variant to proteolysis. As described above, in the specification and claims, a "sub-sequence" means a sequence which is capable of being cleaved by a protease when tropoelastin or a tropoelastin variant is folded in a functional conformation. The sub-sequences correspond to the amino acid sequences in the regions of tropoelastin which are susceptible to proteolysis. Typically, at least one sub-sequence is inserted into the tropoelastin or tropoelastin variant amino acid sequence. Preferably the

tropoelastin is human tropoelastin.

In one embodiment of the fifth aspect of the invention, the inserted sub-sequence is capable of being digested by a serine protease and has an amino acid

5 sequence including the sequence RAAAG [aa 1-5 of SEQ ID NO: 9], or an amino acid sequence selected from the group of sequences shown in SEQ ID NOS: 17 to 44. Preferably, the sub-sequence is capable of being digested by thrombin and has an amino acid sequence shown in SEQ ID NOS: 8 or 9.

10 Preferably the sub-sequence is capable of being digested by plasmin and has an amino acid sequence shown in SEQ ID NOS: 11 or 12. More preferably, the sub-sequence is capable of being digested by kallikrein. Yet more preferably, the sub-sequence is capable of being digested by kallikrein and  
15 has an amino acid sequence shown in SEQ ID NOS: 9 or 10.

In another embodiment of the fifth aspect of the invention, the sub-sequence is capable of being digested by a metalloproteinase and has an amino acid sequence including the sequence: ALAAA [aa 1-5 of SEQ ID NO:13], or  
20 an amino acid sequence selected from the group of sequences shown in SEQ ID NOS: 45 to 70. Preferably, the sub-sequence is capable of being digested by gelatinase A or B. Preferably the sub-sequence has the amino acid sequence shown in SEQ ID NO: 13.

25 In a sixth aspect the invention provides an enhanced tropoelastin derivative exhibiting enhanced susceptibility to proteolysis in comparison with a corresponding tropoelastin or tropoelastin variant, the enhanced tropoelastin derivative characterised in that a sub-  
30 sequence is inserted in the amino acid sequence of the enhanced tropoelastin derivative to enhance the susceptibility of the enhanced tropoelastin derivative to proteolysis. Typically, at least one sub-sequence is inserted into the tropoelastin or tropoelastin variant  
35 amino acid sequence. Preferably the tropoelastin is human

tropoelastin.

In one embodiment of the sixth aspect of the invention, the inserted sub-sequence is capable of being digested by a serine protease. Preferably the inserted sub-sequence includes the sequence RAAAG [aa 1-5 of SEQ ID NO:9], or is a sequence selected from the group of sequences shown in SEQ ID NOS: 17 to 44. Preferably the inserted sub-sequence is capable of being digested by thrombin, and the inserted sub-sequence has the sequence shown in SEQ ID NOS: 8 or 9. Preferably the inserted sub-sequence is capable of being digested by plasmin, and the inserted sub-sequence has the sequence shown in SEQ ID NOS: 11 or 12. More preferably, the inserted sub-sequence is capable of being digested by kallikrein. Yet more preferably, the inserted sub-sequence is capable of being digested by kallikrein and the inserted sub-sequence has the sequence shown in SEQ ID NOS: 9 or 10.

In another embodiment of the sixth aspect of the invention, the inserted sub-sequence is capable of being digested by a metalloproteinase. Preferably the inserted sequence includes the sequence: ALAAA [aa 1-5 of SEQ ID NO:13], or is a sequence selected from the group of sequences shown in SEQ ID NOS: 45 to 70. More preferably, the inserted sub-sequence is capable of being digested by gelatinase A or B. More preferably, the inserted sub-sequence is capable of being digested by gelatinase B and the inserted sub-sequence has the sequence shown in SEQ ID NO: 13.

The enhanced tropoelastin derivative of the sixth aspect can beneficially be used *in vivo* at sites where it is desirable to augment protease attack on the derivative. Suitable molecules for manipulation include human tropoelastin molecules. In this case, the modified tropoelastin will be of use in situations in which it is desirable to have the tropoelastin or tropoelastin variant



degrade rapidly. Such situations include revealing and/or release of peptides with desirable properties, to accelerate tissue repair.

As the inventor has determined the regions of  
5 tropoelastin which are susceptible to proteolysis, the susceptibility of a polypeptide to proteolysis can be modified by inserting a sequence which corresponds to an amino acid sequence in a susceptible region of  
10 tropoelastin, into the polypeptide amino acid sequence, thus providing a polypeptide derivative which has enhanced protease susceptibility under particular conditions compared with the same polypeptide which does not contain the said inserted sequence, (the corresponding polypeptide) under the same conditions.

15 In the specification and claims "polypeptide derivative" means a polypeptide produced by inserting a sequence which corresponds to an amino acid sequence in a susceptible region of tropoelastin, into the polypeptide sequence. The insertion of the amino acid sequence which  
20 corresponds to the amino acid sequence of a susceptible region of tropoelastin into the polypeptide sequence, causes the enhanced protease susceptibility of the polypeptide derivative.

Insertion of the amino acid sequence into the  
25 polypeptide sequence may occur by, for example, splicing a peptide which has an amino acid sequence which corresponds to a susceptible region in tropoelastin, into the polypeptide. Thus polypeptide derivatives may be produced by mutation events including a mutation in a nucleotide  
30 sequence which causes an insertion of a peptide in the polypeptide amino acid sequence wherein the inserted peptide corresponds to an amino acid sequence in a susceptible region of tropoelastin.

Alternatively, insertion of the amino acid sequence  
35 into the polypeptide sequence may occur by modifying an

amino acid sequence in the region of the polypeptide, by residue insertion, substitution or deletion, so as to generate an amino acid sequence in that region of the polypeptide which is the same as an amino acid sequence in a susceptible region of tropoelastin. Thus, polypeptide derivatives may be produced by mutation events including a mutation in a nucleotide sequence which causes residue insertion, substitution or deletion in a region of the polypeptide, wherein the mutation events produce at the region, an amino acid sequence which corresponds to a susceptible region of tropoelastin.

Polypeptide derivatives which contain these mutations may be produced synthetically or by recombinant DNA methods.

Thus in a seventh aspect the invention provides a method for enhancing the susceptibility of a polypeptide amino acid sequence to proteolysis, which method comprises inserting an amino acid sequence which corresponds to an amino acid sequence in a susceptible region of tropoelastin into the polypeptide amino acid sequence to enhance the susceptibility of the polypeptide to proteolysis. Typically at least one amino acid sequence corresponding to an amino acid sequence in a susceptible region of tropoelastin is inserted into the polypeptide amino acid sequence.

In one embodiment the inserted sequence is capable of being digested by a protease selected from the group consisting of thrombin, kallikrein, trypsin and related serine proteases including elastase. In another embodiment, the inserted sequence is digested by metalloproteinase.

In an eighth aspect, the invention provides a polypeptide derivative exhibiting enhanced susceptibility to proteolysis in comparison with a corresponding polypeptide, the polypeptide derivative characterised in

that an amino acid sequence which corresponds to an amino acid sequence in a susceptible region of tropoelastin is inserted into the polypeptide amino acid sequence to enhance the susceptibility of the polypeptide to

5 proteolysis. Typically at least one sequence corresponding to an amino acid sequence in a susceptible region of tropoelastin is inserted into the polypeptide amino acid sequence.

10 In one embodiment, the inserted sequence is capable of being digested by a serine protease. Preferably the serine protease is kallikrein. In another embodiment the inserted sequence may be digested by a metalloproteinase.

As the inventor has determined the regions of tropoelastin which are susceptible to proteolysis, these  
15 regions can be used to direct the specific release of peptide domains from reduced or enhanced tropoelastin derivatives of the second and sixth aspects of the invention or the specific release of peptides from the polypeptide derivatives of the eighth aspect of the  
20 invention. Typically, amino acid sequences which correspond to the susceptible regions of tropoelastin are inserted between the derivative and the peptide domain thus providing a chimeric derivative which can be digested at the susceptible region by a specific protease to release  
25 the peptide domain from the derivative.

In the specification and claims, "chimeric derivative" means a molecule produced by linking a derivative selected from the group consisting of a reduced tropoelastin derivative, enhanced tropoelastin derivative and a  
30 polypeptide derivative, with a peptide domain via an amino acid sequence which corresponds to an amino acid sequence in a susceptible region of tropoelastin. The amino acid sequence which corresponds to the amino acid sequence of a susceptible region of tropoelastin causes the release of  
35 the peptide domain from the derivative when the chimeric

derivative is digested by a specific protease.

Chimeric derivatives may be produced by recombinant DNA techniques, including for example the construction of a nucleotide sequence which encodes the derivative, the  
5 susceptible region and the peptide domain in a single open reading frame. The chimeric derivatives may alternatively be produced synthetically or by recombinant DNA methods.

Thus in a ninth aspect, the invention provides a method for producing a chimeric derivative which method  
10 comprises linking a derivative selected from the group consisting of a reduced tropoelastin derivative, enhanced tropoelastin derivative and a polypeptide derivative, with a peptide domain via an amino acid sequence which corresponds to an amino acid sequence in a susceptible  
15 region of tropoelastin.

In one embodiment, the amino acid sequence which corresponds to an amino acid sequence in a susceptible region of tropoelastin sequence may be digested by a serine protease. Preferably the serine protease is kallikrein.  
20 In another embodiment the sequence may be digested by a metalloproteinase.

In a tenth aspect, the invention provides a chimeric derivative which comprises a derivative selected from the group consisting of a reduced tropoelastin derivative,  
25 enhanced tropoelastin derivative and a polypeptide derivative, which is linked with a peptide domain via an amino acid sequence which corresponds to an amino acid sequence in a susceptible region of tropoelastin.

In one embodiment the amino acid sequence which  
30 corresponds to an amino acid sequence in a susceptible region of tropoelastin sequence may be digested by a serine protease. Preferably the serine protease is kallikrein. In another embodiment the sequence may be digested with metalloproteinase.

35 The chimeric derivatives of the invention are useful

where the peptide domain has a particular biological function, including for example chemotaxis, cell proliferation or cell activation. These biological functions are effected by digestion of the chimeric derivative at the sub-sequence by a particular protease so as to release the peptide domain from the derivative domain.

The mutations in accordance with this invention may be generated by conventional site-directed or random mutagenesis. Oligonucleotide-directed mutagenesis is a further option. This method comprises:

1. synthesis of an oligonucleotide with a sequence that contains the desired nucleotide substitution (mutation);
2. hybridising the oligonucleotide to a template comprising a structural sequence encoding tropoelastin; and
3. using a DNA polymerase to extend the oligonucleotide as a primer.

Another approach which is particularly suited to situations where a synthetic polynucleotide encoding the tropoelastin is prepared from oligonucleotide blocks bounded by restriction sites, is cassette mutagenesis where entire restriction fragments are replaced.

As the inventor has identified regions of tropoelastin which are susceptible to proteolysis, it is possible to use the amino acid sequences in the susceptible regions to prepare protease inhibitor molecules which are also known as peptidomimetic molecules. In the specification and claims, "peptidomimetic molecules" means molecules which imitate a region of tropoelastin which is susceptible to proteolysis, and which therefore compete with the susceptible region for the catalytic domain in a protease. Typically the peptidomimetic molecules are peptides or peptide -like.

The peptidomimetic molecules of the invention may be

structurally similar to peptides. They may include an amino acid sequence of a tropoelastin or of a variant of tropoelastin which is or includes a proteolytic site. The peptidomimetic molecules of the invention may include amino acid residues which are modified at one or more chemical groups and may be linked by non-peptide bonds. These molecules can be used in situations in which it is desirable to prevent the action of the relevant proteases.

In an eleventh aspect the present invention provides a peptide or a peptidomimetic molecule including all or part of a peptide selected from the group consisting of KAPGVGGAF [SEQ ID NO:8], RAAAGLG [SEQ ID NO: 9], RSLSPELREGD [SEQ ID NO: 10], KAAQFGLVPGV [SEQ ID NO: 11], KSAAKVAAKAQLRAA [aa 505-519 of SEQ ID NO:4], RSLSPELRE [aa 1-9 of SEQ ID NO: 4] and LAAAKAAKYGAA [aa 2-13 of SEQ ID NO:13].

The peptides of this aspect of the invention may be short peptides consisting of all or part of a sequence selected from the group consisting of KAPGVGGAF [SEQ ID NO:8], RAAAGLG [SEQ ID NO: 9], RSLSPELREGD [SEQ ID NO: 10], KAAQFGLVPGV [SEQ ID NO: 11], KSAAKVAAKAQLRAA [aa 505-519 of SEQ ID NO:4], RSLSPELRE [aa 1-9 of SEQ ID NO: 4] and LAAAKAAKYGAA [aa 2-13 of SEQ ID NO:13] each in combination with upstream sequence to generate a peptide typically of the order of 15 residues although it will be understood that in some cases smaller peptides could be used and frequently larger sequences could be used. The peptides can be larger molecules containing one or more of these sequences. In addition structural analogues of these peptides are included within the scope of peptidomimetic molecules of the invention, and include for instance molecules containing modified amino acid residues.

A preferred molecule is one in which the natural cleavage site would typically be located about the centre of the peptide or peptidomimetic molecule. An example

peptide is H-Ala-Ala-Lys-Ala-Gln-Leu-Arg-Ala-Ala-Ala-Gly-Leu-Gly-Ala-OH [aa 511-524 of SEQ ID NO:4] which is based on the sequence RAAAGLGA [SEQ ID NO:9], in its context within the sequence of tropoelastin(s). A peptidomimetic  
5 form of this molecule is H-Ala-Ala-Lys-Ala-Gln-Leu-Arg-R-Ala-Ala-Ala-Gly-Leu-Gly-Ala-OH (where R = a reduced peptide bond) [SEQ ID NO:83]. Also preferred are the following retro-inverso pseudo peptides: H-D-Ala-Gly-D-Leu-Gly-D-Ala-D-Ala-D-Ala-(reduced)-D-Arg-D-Leu-D-Gln-D-Ala-D-  
10 Lys-D-Ala-D-Ala-OH [SEQ ID NO:84] and H-D-Ala-Gly-D-Leu-Gly-D-Ala-D-Ala-D-Ala-D-Arg-D-Leu-D-Gln-D-Ala-D-Lys-D-Ala-D-Ala-OH [SEQ ID NO: 85]. Preferably these peptides are coupled to a substrate through the N- or C- terminus.

Also preferred are the following peptides: H-Val-Pro-  
15 Gly-Ala-Leu-Ala-Ala-Ala-OH [aa 557-564 of SEQ ID NO:5]; H-Val-Pro-Gly-Ala-(reduced)-Leu-Ala-Ala-Ala-OH [SEQ ID NO: 86] and the retro-inverso pseudopeptides: H-D-Ala-D-Ala-D-Ala-D-Leu-(reduced)-D-Ala-Gly-D-Pro-D-Val-OH [SEQ ID NO: 87] and H-D-Ala-D-Ala-D-Ala-D-Leu-D-Ala-Gly-D-Pro-D-Val-OH  
20 [SEQ ID NO: 88]. Preferably these peptides are coupled to a substrate through the N- or C- terminus.

A further category of molecules contain one or more attached reactive groups for the covalent modification of an interacting protease leading to further inhibition of  
25 activity of the protease. The invention contemplates the use of endogenous or exogenous lysyl oxidase for attaching reactive groups. It is also recognised that there is a plethora of chemically reactive groups available as biochemical reagents, which are often utilised in the  
30 construction of chemical crosslinkers. The invention contemplates the use of endogenous or exogenous lysyl oxidase for attaching reactive groups. A subset of these may be found in the Pierce Product Catalog (1997) Chapter 7 pp133 to 154. The reactive group is placed at the ends or  
35 internal to the molecule to provide a proximity to the

reacting entity.

The peptides and peptidomimetic molecules of the invention are useful in a number of different environments including in the purification of tropoelastin, as a  
5 pharmaceutical agent which can be provided in an inhalant form for protecting lung tissue from damage related to elastolytic protease attack on elastin (a major cause of lung damage in smokers) and in any other environment in which competitive inhibition of protease active sites  
10 recognising these peptides is desirable.

The peptides and peptidomimetic molecules of the invention are also useful in inhibiting or controlling the local growth and metastases of cancer. In particular, the inventors recognise that the peptides and peptidomimetic  
15 molecules of the invention will be useful in competing with endogenous tropoelastin for proteases which are secreted by neoplastic cells. The secretion of these proteases is typically associated with the local growth or metastases of cancer. Thus the capacity of the peptide or peptidomimetic  
20 molecules of the invention to compete with endogenous tropoelastin for the proteases may inhibit or reduce the local growth or metastasis of the cancer. In this application, the peptides or peptidomimetic molecules of the invention may be coupled to a substrate.

25 In a twelfth aspect the present invention provides a method for enhancing the purification of a tropoelastin or a tropoelastin variant which method comprises including at least one peptide or peptidomimetic molecule of the eleventh aspect of the invention in the crude tropoelastin  
30 or tropoelastin variant preparation which is being subjected to purification.

In a thirteenth aspect the present invention provides a pharmaceutical composition comprising a derivative selected from the group consisting of a reduced  
35 tropoelastin derivative, an enhanced tropoelastin



derivative, a polypeptide derivative and a chimeric derivative, or a peptide or peptidomimetic molecule of the invention together with a pharmaceutically acceptable carrier or diluent. Formulations of the derivatives or  
5 peptides or peptidomimetic molecules of the present invention are prepared in accordance with standard pharmaceutical techniques. Preferred formulations in accordance with the invention include inhalant formulations, incorporation into emulsions designed for  
10 localised use, attachment to surfaces such as a stent and injectable formulations. In addition the present inventor recognises that the compositions of the invention can be adapted for use in situations in which it is desirable to limit protease activity such as that leading to clot  
15 formation.

In an fourteenth aspect the present invention provides a nucleotide sequence encoding a derivative selected from the group consisting of a reduced tropoelastin derivative, an enhanced tropoelastin derivative, a polypeptide  
20 derivative and a chimeric derivative or a peptide or peptidomimetic molecule of the invention.

The nucleotide may be provided as a recombinant DNA molecule including vector DNA. Polynucleotides can be prepared using a combination of synthetic and cDNA  
25 techniques to form hybrid modified polynucleotide molecules. These molecules also fall within the scope of this invention.

Vectors useful in this invention include plasmids, phages and phagemids. The synthetic polynucleotides of the  
30 present invention can also be used in integrative expression systems or lytic or comparable expression systems.

Suitable vectors will generally contain origins of replication and control sequences which are derived from  
35 species compatible with the intended expression host.

Typically these vectors include a promoter located upstream from the polynucleotide, together with a ribosome binding site if intended for prokaryotic expression, and a phenotypic selection gene such as one conferring antibiotic resistance or supplying an auxotrophic requirement. For production vectors, vectors which provide for enhanced stability through partitioning may be chosen. Where integrative vectors are used it is not necessary for the vector to have an origin of replication. Lytic and other comparable expression systems do not need to have those functions required for maintenance of vectors in hosts.

For *E. coli* typical vectors include pBR322, pBluescript II SK<sup>+</sup>, pGEX-2T, pTrc99A, pET series vectors, particularly pET3a and pET3d, (Studier *et al.*, 1990) and derivatives of these vectors.

In a fifteenth aspect the present invention provides a cell containing a nucleotide sequence of the fourteenth aspect of the invention.

A preferred expression system is an *E. coli* expression system. However, the invention includes within its scope the use of other hosts capable of expressing protein from the polynucleotides designed for use in *E. coli* as well as to the use of synthetic polynucleotides suitable for use in other expression systems such as other microbial expression systems. These other expression systems include yeast, and bacterial expression systems, insect cell expression systems, and expression systems involving other eukaryotic cell lines or whole organisms.

Examples of *E. coli* hosts include *E. coli* B strain derivatives (Studier *et al.*, 1990), NM522 (Gough and Murray, 1983) and XL1-Blue (Bullock *et al.*, 1987).

In a sixteenth aspect the present invention provides an expression product of a cell of the fifteenth aspect of the invention encoded by a nucleotide sequence of the fourteenth aspect of the invention.

The expression products of the invention may be fused expression products which include all or part of a protein encoded by the vector in peptide linkage with the expression product. They may also include, for example, an N-terminal methionine or other additional residues which do not permanently impair the elastic properties of the product.

Typically the fusion is to the N-terminus of the desired expression product. An example of a suitable protein is glutathione S-transferase (Smith and Johnson 1988). The fused protein sequence may be chosen in order to cause the expression product to be secreted or expressed as a cell surface protein to simplify purification or expressed as a cytoplasmic protein.

The expressed fusion products may subsequently be treated to remove the fused protein sequences to provide free modified tropoelastin. Treatment is typically through protease treatment, or in the case of secretion removal is effected by endogenous host secretion machinery. An example of this is secretion by yeasts, including but not limited to *S. cerevisiae* and *S. pombe*.

Non-fused systems include the introduction of or use of a pre-existing methionine codon. An example of this is the use of pET3a and pET3d in *E. coli*.

According to a seventeenth aspect of the present invention there is provided a process for the production of an expression product of the sixteenth aspect comprising:

providing a cell of the fifteenth aspect; culturing it under conditions suitable for the expression of the product of the sixteenth aspect; and collecting the expression product.

In an eighteenth aspect the present invention provides an implant formed from one or more derivatives selected from the group consisting of a reduced tropoelastin derivative, an enhanced tropoelastin derivative, a

polypeptide derivative and a chimeric derivative. Where the derivative has reduced proteolytic susceptibility the implant will be intended to be maintained *in situ* over a considerable period of time whereas when the derivative has enhanced proteolytic susceptibility the implant will be intended to be maintained *in situ* over a short period of time and indeed the rapid dissolution of the implant will be desired such as where it is desired that the implant is replaced by endogenous connective tissue.

10 Tropoelastin derivatives (ie reduced tropoelastin derivatives and enhanced tropoelastin derivatives) of the invention can be cross-linked to form elastin or elastin-like material or can be cross-linked in conjunction with other biological or synthetic molecules to form a composite material. The cross-linking of the tropoelastin derivative can be achieved by chemical oxidation of lysine side chains using processes such as ruthenium tetroxide mediated oxidation and quinone mediated oxidation, or by using bifunctional chemical cross-linking agents such as dithiobis (succinimidylpropionate), dimethyl adipimidate or dimethyl pimelimidate and those within heterologous sites such as agents that contain UV activated cross-linking domain(s). Another alternative is the cross-linking of lysine and glutamic acid side chains.

25 The tropoelastin derivatives (ie reduced tropoelastin derivatives and enhanced tropoelastin derivatives) may also be enzymatically cross-linked by methods including lysyl oxidase mediated oxidation or be cross-linked using gamma irradiation. The implants are formed into the required shape by cross-linking the tropoelastin derivative in a mould which conforms to the desired shape of the implant. Where the implant is required to be used in sheet form the derivative can be cross-linked on a flat surface. Relevant methodologies are described in, for example, US 4 474 851 and US 5 250 516. The elastomeric materials may be

exclusively prepared from one or more derivatives or may be composites prepared from one or more derivatives together with other materials.

5

~~———BRIEF DESCRIPTION OF THE DRAWINGS~~

~~———Figure 1 shows a schematic diagram illustrating the relative positions of protease sites identified by N-terminal sequencing for serum, kallikrein and thrombin.~~

10 ~~Major sites are indicated with a solid bar while minor sites are indicated with a stippled bar. Since most plasmin fragments contained the same N-terminal sequence the site of cleavage could not be identified unambiguously. The trypsin fragments identified similarly all contained~~  
15 ~~the same N-terminal sequence. Therefore, the likely regions of cleavage for plasmin and trypsin are not shown.~~

~~———Figure 2 shows the nucleotide sequence and amino acid sequence of SHEL. The positions of the protease recognition sites are underlined. The amino acid of SHEL is shown in SEQ ID NO:4.~~

20

~~———Figure 3 shows the amino acid sequence of SHELδ26A (bottom line) compared to the amino acid sequence of SHEL. The amino acid sequence of SHELδ26A is shown in SEQ ID NO:5.~~

25 ~~———Figure 4 shows the nucleotide sequence and amino acid sequence of SHELδmod. The amino acid sequence of SHELδmod is shown in SEQ ID NO:6.~~

~~———Figure 5 shows 10% SDS PAGE analysis of SHEL with serum after incubation for 1,2,3 or 18 hours (Lanes 1 to~~  
30 ~~4). Lanes 5 and 6: peptide fragments produced by serum digestion of SHEL and SHELδ26A respectively, purified by butanol solubilisation. Approximate sizes of fragments produced are shown in kDa. Size markers are shown in kDa.~~

~~———Figure 6 shows 8% SDS PAGE analysis of the effect of~~  
35 ~~protease inhibitors on serum degradation of SHEL. Lanes 1,~~

3, 5, 7 and 9: SHEL incubated with serum; lane 2: SHEL incubated with serum and 0.5mM Pefabloc SC; lane 4: SHEL incubated with serum and 5mM PMSF; lane 6: SHEL incubated with serum and EDTA; lane 8: SHEL incubated with serum and 50 mM Pefabloc PK; and lane 10: SHEL incubated with serum and 1 unit Hirudin.

Figure 7 shows 8% SDS PAGE analysis of the effect of thrombin on SHEL and SHEL $\delta$ 26A. Increasing amounts of thrombin: lane 1 (0.01 units); lane 2 (0.05 units); lane 3 (0.10 units); lane 4 (0.15 units); lane 5 (0.20 units) and lane 6 (0.25 units) were added to SHEL. Lanes 7 and 8: effect of thrombin (1U) on degradation of SHEL and SHEL $\delta$ 26A respectively. Fragment sizes are estimated in kDa. Size markers are shown in kDa.

Figure 8 shows 8% SDS PAGE analysis of the effect of kallikrein on SHEL and SHEL $\delta$ 26A. Increasing concentrations of kallikrein: lane 1:  $3.0 \times 10^{-4}$ ; lane 2:  $6.0 \times 10^{-4}$ ; lane 3:  $1.5 \times 10^{-3}$  and lane 4:  $3.0 \times 10^{-3}$  were added to SHEL. Lanes 5 and 6: effect of kallikrein ( $6 \times 10^{-4}$ U) on degradation of SHEL and SHEL $\delta$ 26A respectively. Fragment sizes and size markers are shown in kDa.

Figure 9 shows 10% SDS PAGE analysis of the effect of bovine trypsin on SHEL and SHEL $\delta$ 26A. Increasing concentrations of bovine trypsin: lane 1:  $5 \times 10^{-4}$ ; lane 2:  $1 \times 10^{-3}$ ; lane 3:  $2 \times 10^{-3}$  and lane 4:  $4 \times 10^{-3}$  were added to SHEL. Lanes 5 and 6: effect of bovine trypsin ( $2 \times 10^{-3}$ U) on SHEL and SHEL $\delta$ 26A respectively. Fragment sizes and size markers are shown in kDa.

Figure 10 shows 10% SDS PAGE analysis of the effect of plasmin on SHEL and SHEL $\delta$ 26A. Increasing concentrations of plasmin: lane 1:  $3.7 \times 10^{-7}$ ; lane 2:  $7.4 \times 10^{-7}$ ; lane 3:  $3.7 \times 10^{-6}$ ; lane 4:  $7.4 \times 10^{-6}$ ; lane 5:  $3.7 \times 10^{-5}$ ; lane 6:  $7.4 \times 10^{-5}$  were added to SHEL. Lanes 7 and 8: effect of plasmin ( $7.4 \times 10^{-5}$ U) on SHEL and SHEL $\delta$ 26A respectively. Fragment sizes and

~~size markers are shown in kDa.~~

~~Figure 11 shows 10% SDS-PAGE analysis of the effect of human leukocyte elastase (HLE) on SHEL and SHEL $\delta$ 26A.~~

~~Increasing concentrations of HLE: lane 1:  $1.6 \times 10^{-4}$ ; lane 2:  $3.2 \times 10^{-4}$ ; lane 3:  $8.0 \times 10^{-4}$ ; lane 4:  $1.6 \times 10^{-3}$ ; lane 5:  $3.2 \times 10^{-3}$  were added to SHEL. Lanes 6 and 7: effect of HLE ( $1.6 \times 10^{-3}$ U) on SHEL and SHEL $\delta$ 26A respectively. Fragment sizes and size markers are shown in kDa.~~

~~Figure 12 shows 10% SDS-PAGE analysis of the effect of S-GAL and SPS-peptide on degradation of SHEL with A: serum, 1/2 dilution 20min; B: trypsin 20min; C: plasmin  $1.5 \times 10^{-5}$ U 20min; D: kallikrein  $15 \times 10^{-4}$ U 40min; E: thrombin 0.1U 20min and F: HLE 70min. Thrombin and kallikrein were used with a 100:1 ratio. Gels were scanned by densitometry and the relative amount of each full-length SHEL band is shown in a histogram.~~

~~Figure 13 shows SDS-PAGE analysis of the effect of coacervation on the degradation of SHEL by proteases. SHEL was incubated in the presence (+) or absence (-) of a concentration of NaCl conducive to coacervation of SHEL at 37°C with A: kallikrein; B: thrombin; C: HLE; D: trypsin; E: plasmin and F: serum; or in the presence (+) or absence (-) of a concentration of NaCl conducive to coacervation of SHEL at 16°C with G: kallikrein; H: thrombin; I: HLE; J: trypsin; K: plasmin and L: serum.~~

~~Figure 14 shows 8% SDS-PAGE gel of the effect of thrombin cleavage of soluble cell lysate containing GST-SHEL. Increasing amounts of thrombin: lane 1: 0.001 unit; lane 2: 0.005 unit; lane 3: 0.010 unit; lane 4: 0.050 unit; lane 5: 0.100 unit; lane 6: 0.500 unit and lane 7: 1.000 unit were added to soluble cell lysate.~~

~~Figure 15 shows the construction scheme for pSHEL $\delta$ 26A. pSHEL $\delta$  and the aberrant pSHEL $\delta$ mod were both digested with SpeI and BssHII. BssHII cuts both plasmids twice and SpeI once resulting in three fragments. The 5424~~

and 946bp fragments from pSHELF and the small 338bp fragment from pSHELF $\delta$ mod were purified from agarose gels. The 5424bp fragment was CIP treated to reduce recircularisation and the three fragments ligated overnight at 16°C using DNA ligase. The final product pSHELF $\delta$ 26A contained the desired deletion of exon 26A from the SHEL gene with no other mutations.

Figure 16 shows a zymogram analysis of SHEL digested with serum (Lane 1), serum with Pefabloc SC (Lane 2) or kallikrein (Lane 3).

Figure 17 shows a zymogram analysis of gelatin digested with serum in the presence of Ca<sup>2+</sup> (Lane 1), Zn<sup>2+</sup> (Lane 2), Ca<sup>2+</sup> and Zn<sup>2+</sup> (Lane 3) and Ca<sup>2+</sup>, Zn<sup>2+</sup> and EDTA (Lane 4).

Figure 18 shows a zymogram analysis of gelatin digested with AMPA activated gelatinase A (Lane 1), unactivated gelatinase A (Lane 2) and serum (Lane 3).

Figure 19 shows protease digestion of SHEL in solution. Lane 1, standards. Lane 2, SHEL. Lane 3, SHEL plus serum. Lane 4, SHEL plus 72kDa gelatinase. Lane 5, SHEL plus 92kDa gelatinase. Lanes 6 and 7, serum plus APMA (1hr incubation), Lanes 8 and 9, serum plus APMA (overnight incubation).

Figure 20 shows human serum kallikrein digestion of SHEL in sodium phosphate buffer, pH7.8 in the presence and absence of urea. Lane 1, standards, Lane 2, SHEL (not incubated), Lane 3, SHEL incubated with buffer (no kallikrein), Lane 4, SHEL plus kallikrein, Lane 5, SHEL plus urea in buffer (no kallikrein), Lane 6, SHEL plus kallikrein in 0.3M urea, Lane 7, SHEL plus kallikrein in 1M urea.

#### BEST METHOD OF PERFORMING THE INVENTION

The recombinant and synthetic procedures used are described in standard texts such as Sambrook et al (1989).



Purification of the tropoelastin derivatives and expression products of the invention is also performed using standard techniques with the actual sequence of steps in each instance being governed by the environment from which the molecule is to be purified. By way of example, reference is made to the purification scheme disclosed in PCT/AU93/00655.

Formulations in accordance with the invention are formulated in accordance with standard techniques.

The amount of tropoelastin derivative or peptidomimetic molecule that may be combined with a carrier or diluent to produce a single dosage form will vary depending on the situation in which the formulation is to be used and the particular mode of administration.

It will be understood also that specific doses for any particular host may be influenced by factors such as the age, sex, weight and general health of the host as well as the particular characteristics of the modified tropoelastin being used, and how it is administered.

Injectable preparations, for example, sterile injectable aqueous or oleagenous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent. Among the acceptable vehicles or solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid and organic solvents find use in the preparation of injectables.

Routes of administration, dosages to be administered

as well as frequency of administration are all factors which can be optimised using ordinary skill in the art.

In addition, the derivatives and expression products may be prepared as topical preparations for instance as  
5 anti-wrinkle and hand lotions using standard techniques for the preparation of such formulations.

They also may be prepared in aerosol form for, for instance, administration to a patient's lungs, or in the form of surgical implants, foods or industrial products by  
10 standard techniques.

#### EXAMPLES

#### 15 MATERIALS AND METHODS

##### Reagents

Hirudin, PMSF, human thrombin, human plasma kallikrein, human plasmin and human leukocyte elastase  
20 (HLE) were obtained from Sigma. Bovine trypsin and Pefabloc SC were from Boehringer-Mannheim and Pefabloc PK was from Pentapharm, Switzerland. Gelatinase A (72kDa gelatinase) and gelatinase B (92kDa gelatinase) were obtained from Boehringer Mannheim Roche Diagnostics.

25 SHEL was obtained by the method described in WO94/14958.

SHEL $\delta$ 26A can be derived from SHEL by removing the synthetic coding sequence corresponding to exon 26A. A comparison of the sequence of SHEL with that of SHEL $\delta$ 26A is  
30 provided at Figure 3. Its protein product is apparently identical to a naturally made human splice form of tropoelastin.

The Transformer Mutagenesis Kit (Clontech USA) was used with pSHELF (described in WO94/14958) in accordance  
35 with the supplied protocol to remove DNA corresponding to

exon 26A. The sequence of the mutagenic primer used (manufactured by Beckman Australia) was:

5' CGG GTT TCG GTG CTG TTC CGG GCG CGC TGG 3' [SEQ ID NO: 89] which flanked either side of exon 26A by 15 bp

5 resulting in its precise deletion. A second selection primer, which mutates a unique restriction site to another restriction site is normally used in the protocol but was not in this case since deletion of exon 26A also resulted in the deletion of a unique restriction site, PmlI. This  
10 enzyme was therefore used to digest the mutation reaction to linearise any unmutated parental plasmid and consequently to enrich for mutant plasmid in accordance with the manufacturer's instructions. The reaction mixture was used to transform competent BMH17-18 *mutS E. coli*  
15 defective in mismatch repair, by electroporation which was performed using a Gene Pulser apparatus (BioRad USA) according to a protocol supplied by the manufacturer. Electrocompetent cells were made according to standard protocol supplied by Clontech. Competent cells were stored  
20 in aliquots at -80°C. After electroporation cells were grown for one hour at 37°C at 280rpm in 1ml LB. The entire entire transformed culture was grown overnight in 5ml LB+ampicillin. Mixed plasmid DNA containing both mutated and parental plasmids was isolated from the culture using  
25 the Qiagen Spin Plasmid® isolation kit and the plasmid DNA was digested with PmlI to linearise the parental plasmid. The plasmid DNA now enriched for mutated plasmid was used to transform *E. coli* HMS174 by electroporation as described above and transformants selected on LB plates containing  
30 75µg/ml ampicillin.

Colonies were grown overnight and plasmid mini-preparations performed in which a single colony was inoculated into 3ml LB+ampicillin media in 10ml screw-topped tubes and grown overnight with shaking at 37°C.  
35 Plasmids were extracted following the alkaline lysis

protocol from Sambrook et al (1989). For HMS174 two extractions with phenol/chloroform/isoamyl alcohol were performed. Constructs were screened using PmlI and those which were insensitive to digestion were further screened by KpnI/PstI double digestion. Candidate clones were sequenced (as described herein) manually using 6F (5' GGG TGT TGG CGT TGC ACC AG 3', SEQ ID NO: 90) and 7R (5' TGC ACC TAC AAC ACC GCC CG 3', SEQ ID NO: 91) primers to confirm sequence integrity either side of the deleted region.

Automated sequencing was conducted (using either the Sequi-Net™ program (Department of Biochemistry Colorado State University USA) or by the SUPAMAC™ program (Sydney University and Prince Alfred Hospital Macromolecular Analysis Centre). DNA was applied after purification by either cesium chloride gradient or Qiagen Tip 20 (Qiagen GmbH Germany) and sequenced using the same primers as for manual sequencing.) using primers 1R (5' TGC CTT TGC CGG TTT GTA CG 3', SEQ ID NO: 92) 3F (5' TCC AGG TGG CTA CGG TCT GC 3', SEQ ID NO: 93) 3R (5' GAG TAC CTA CGC CTG CGA TAC 3', SEQ ID NO: 94) 5R (5' GGA GTA CCA ACG CCG TAC TT 3', SEQ ID NO: 95) 6F (5' GGG TGT TGG CGT TGC ACC AG 3', SEQ ID NO: 96) 7R (5' TGC ACC TAC AAC ACC GCC CG 3', SEQ ID NO: 97) pETforward (5' GCA CTC ACT ATA GGG AGA CC 3', SEQ ID NO: 98) pETreverse (5' GCC AAC TCA GCT TCC TTT CG 3', SEQ ID NO: 99) was performed to verify the rest of the sequence. A number of undesired mutations were discovered necessitating further manipulation to the DNA. The mutated DNA is named pSHELFδmod.

Sequencing confirmed the region immediately surrounding the deletion was correct. PstI and BssHII restriction sites surrounding the correct region of pSHELFδmod was used to remove the desired segment and reinsert it into the corresponding site of pSHELF.

6.5µg pSHELF and 7.5µg pSHELFδmod were digested with BssHII precipitated and digested with PstI. The appropriate three fragments (Figure 15) were gel purified and ligated using 1U DNA ligase (Boehringer Mannheim Germany) overnight at 16°C. DNA was transformed into *E. coli* XL1-Blue and transformants selected on plates containing 75µg/ml ampicillin.

Plasmids were isolated by mini-preparations and screened using BglI digestion. A candidate clone was further analysed by restriction enzyme digestion and automated sequencing was then performed using primers 1R, 3F, 5R, 6F, 7R and T7 forward (5' TAA TAC GAC TCA CTA TAG GG 3', SEQ ID NO: 100) to confirm the entire sequence. The correct sequence was designated pSHELFδ26A.

SHELFδ26A displays higher protease resistance than SHELF.

#### Serum Proteolysis of SHELF

Human serum was obtained from fresh intravenous blood, centrifuged at 2000g to remove red blood cells and then allowed to clot before serum was removed. Aliquots (20µl) were stored at -20°C and thawed when needed. 15µg tropoelastin in 50mM sodium phosphate buffer, pH 7.8 was incubated with 0.5µl serum in a 20µl reaction for between 1 and 18hr at 37°C. Similar experiments were conducted with or without the prior addition of inhibitors. Inhibitors were added at the following concentrations; 0.5 or 1Uhirudin, 0.5 or 5mM Pefabloc SC, 1 or 5mM PMSF, 25mM EDTA, 50 or 250µM Pefabloc PK. All inhibitors were dissolved in water except PMSF which was dissolved in isopropanol. Reactions were analysed by 8% SDS-PAGE. Serum-digested peptides to be used for sequencing were purified by the addition of 1.5 volumes n-propanol, followed by 2.5 volumes n-butanol and stirred overnight.

The organic solvents were removed by rotary evaporation and peptides resuspended in 50mM sodium phosphate buffer, pH 7.8.

## 5 Proteolytic Assays

A range of enzyme concentrations was originally used to determine the optimal amount for subsequent experiments. Thrombin ( $0.01-1\text{U}$ ), human plasma kallikrein ( $3 \times 10^{-4}$  to  $3 \times 10^{-3}\text{U}$ ), human plasmin ( $7 \times 10^{-5}$  to  $4 \times 10^{-7}\text{U}$ ), bovine trypsin ( $5 \times 10^{-4}$  to  $4 \times 10^{-3}\text{U}$ ), and human leukocyte elastase ( $1.6 \times 10^{-4}$  to  $3.2 \times 10^{-3}\text{U}$ ) were added to  $10\mu\text{g}$  SHEL or SHEL $\delta$ 26A in 50mM sodium phosphate buffer pH 7.8 in a total volume of  $20\mu\text{l}$ . All reactions were performed at  $37^\circ\text{C}$  for one hour. Gelatinase A and B were activated using 0.8mM APMA at  $37^\circ\text{C}$  for 30 minutes (gelatinase A) or  $37^\circ\text{C}$  for 45 minutes (gelatinase B). Gelatinase A ( $4 \times 10^{-3}$  -  $4 \times 10^{-2}$ ) and gelatinase B ( $2 \times 10^{-5}$  -  $1 \times 10^{-4}$ ) was added to 15mg SHEL or SHEL $\delta$ 26A in a total volume of 50mL. Gelatinase B reactions were performed in the presence of 0.75mM APMA. The degradation profile was analysed by 8, 10 or 12% SDS-PAGE.

## Zymogram analysis

8 or 10% zymogram gels were run using (1mg/ml) porcine gelatin or SHEL as the substrate. After electrophoresis, gels were washed in  $2 \times 100\text{mL}$  2.5% Triton-X 100 for 20 minutes, followed by  $2 \times 100\text{mL}$  50mM Tris-HCl pH7.8, 30mM NaCl for 5 minutes and incubated overnight at  $37^\circ\text{C}$  in 50mM Tris-HCl pH 7.8, 30mM NaCl, 5 mM  $\text{CaCl}_2$ . Gels were fixed with 25% isopropanol, 10% acetic acid, washed with  $3 \times 200\text{mL}$  water and stained using Gelcode (Pierce).

## N-terminal sequencing

Gels were poured using fresh acrylamide stocks and half the usual amounts of APS and TEMED. Gels were allowed to set for 16-24hrs. For simple protein profiles, gels

were pre-run at room temperature for four hours at 20mA using 150mM Tris HCl pH8.8 buffer with 10µl/L thioglycollic acid in the upper buffer chamber. Samples were loaded and run at 4°C with fresh buffer for approximately three hours.

5 For more complex profiles gels were pre-run at room temperature in Tris-glycine buffer (25mM Tris HCl, 192mM glycine, 0.1% (w/v) SDS, pH approximately 8.3), fresh buffer added and the gel allowed to equilibrate to room temperature before samples were added and run at 20mA with  
10 10µl/L thioglycollic acid added to the upper chamber. Pre-stained standards (Kaleidoscope; Biorad, USA) were used to monitor extent of migration.

Gels were blotted onto polyvinylidene difluoride (PVDF) membrane (ProBlott, Applied Biosystems USA) treated  
15 according to manufacturer's instructions, overnight at 70mA using 10mM CAPS pH 11.0, 10% methanol, 10 µl/L thioglycollic acid buffer at 4°C with stirring. Blotting was performed using a Hoefer Transblot apparatus and was used according to manufacturer's instructions. The  
20 membrane was stained with 0.1% Coomassie blue-R in 50% methanol and destained in 50% methanol, 10% acetic acid. The membrane was washed with water overnight before being air-dried. Bands were excised with a clean scalpel. Samples were blotted onto PVDF as described above. Bands  
25 were excised with a clean scalpel and sequenced by Sydney University and Prince Alfred Hospital Macromolecular Analysis Centre (SUPAMAC) using Applied Biosystems hardware and protocols. Alternatively samples were sent to the Biomolecular Resource Facility Australian National  
30 University, Canberra, for sequencing.

#### Peptide Preparation and Use

S-GAL, N-VVGSPSAQDEASPLS-C [SEQ ID NO: 101], is a peptide representing the elastin binding domain of EBP  
35 (Hinek and Rabinovitch 1994). It was synthesised by Chiron

Mimotopes (Australia) and purified by RP-HPLC as follows. Concentrated peptide in 50mM ammonium acetate was treated by RP-HPLC initially by perfusion chromatography (POROS, PerSeptive Biosystems USA) using an R2 reverse phase  
5 column (4.6 x 100mm) run at 9ml/min along a 0-100% acetonitrile, 0.1% trifluoroacetic acid (TFA) gradient over 7min was used. Alternatively, a Techogel10 C18 column (2.2 x 25cm) was used with a flow rate of 8ml/min. A 0-100% acetonitrile, 0.1% TFA gradient over 55 min was used after  
10 a 10min initial wash with 30% acetonitrile/0.1% TFA. The column was equilibrated for 10min between runs due to its large volume. A maximum of 30-50mg peptide was loaded at any one time. For both methods sample detection was at 214 and 280nm simultaneously. Both methods were performed  
15 using Pharmacia (Sweden) pumps and detectors. The solution was removed from the collected samples by lyophilisation and purified peptide weighed to determine yield.

A large molar excess of S-GAL in Milli-Q water (10 to 200 fold) was added to 15µg SHEL in 50mM sodium phosphate  
20 pH7.8 made up to a total volume of 40µl and preincubated at 37°C for one hour as suggested by Hinek and Rabinovitch (1994) before the selected protease (kallikrein,  $6-15 \times 10^{-4}$ U; thrombin 0.1-0.2U; trypsin  $2 \times 10^{-3}$ U; plasmin,  $1.5-3.7 \times 10^{-5}$ U; human leukocyte elastase,  $1.6 \times 10^{-3}$ U; serum 1µl) was  
25 added according to the optimal amounts determined above for 10 to 80 minutes. Various dilutions of serum from ½-1/50 in 50mM sodium phosphate pH7.8 were used and both SHEL and SHELδ26A were used for each experiment.

A peptide representing a region of SHEL cleaved by a  
30 selection of serine proteases: N-AAKAQLRAAGLGA-C (serine protease site peptide, SPS-peptide, aa 511-524 of SEQ ID NO:4) was synthesised by Chiron Mimotopes (Australia) to test whether its presence could protect SHEL from  
degradation by acting as a competitor. Experiments were  
35 conducted in parallel with S-GAL using identical procedures



(see above). Both SHEL and SHELδ26A were used. Each reaction was analysed by 10% SDS-PAGE. Gels were scanned by densitometry and the volume of full-length SHEL calculated as follows. Scanning densitometry of stained gels was performed using the Molecular Dynamics Personal Densitometer. Images were analysed and quantitated using ImageQuant software (Version 3.2, Molecular Dynamics USA).

#### 10 Proteolysis During Coacervation

10mg/ml SHEL in 50mM sodium phosphate pH7.8 and 150mM NaCl was allowed to coacervate at 37°C until cloudy before adding human plasma kallikrein ( $6 \times 10^{-4}$ U), thrombin (1U), plasmin ( $1.5 \times 10^{-5}$ U), trypsin ( $2 \times 10^{-3}$ U),  
15 HLE ( $1.6 \times 10^{-3}$ U) and serum (0.75μl) for one hour. Control reactions were performed at 16°C for three hours. Extent of proteolysis was monitored by SDS-PAGE.

## RESULTS

20

### A. Degradation of SHEL by Serum

Human tropoelastin was degraded by human serum into discrete bands, resistant to further degradation. The same degradation profile was seen by SDS-PAGE with overnight  
25 incubation as with incubations left for one hour (Figure 5). Figure 5 clearly shows the peptide fragments after purification from serum using butanol. The sizes of the major bands are approximately 50, 45, 35, 28, 27, 25, 22 and 18 kDa, visually similar to that obtained by Romero et  
30 al (1986) using porcine tropoelastin. The pattern of peptides produced was reproducible over many separate experiments. Similar results were obtained with SHELδ26A (Figure 5) but the 22 and 18kDa bands were absent and replaced by a 15kDa band.

35

## B. Effect of Protease Inhibitors on Serum Degradation

Figure 6 shows the amount of full-length SHEL after incubation with serum in the presence or absence of various protease inhibitors. Wide-spectrum serine protease inhibitors were found to inhibit degradation since both Pefabloc SC and PMSF protected tropoelastin from cleavage (Figure 6). In contrast, EDTA which is an inhibitor of metalloproteinases, appeared to promote digestion. This is an unexpected result because the metalloproteinases gelatinase A and gelatinase B digest tropoelastin (Figure 19). Protease inhibitors specific for the serine proteases thrombin and kallikrein were also tested. Hirudin, a highly specific inhibitor of thrombin, did not appear to significantly inhibit degradation whereas Pefabloc PK, specific for kallikrein, inhibited proteolysis (Figure 6).

## C. Degradation of SHEL with specific proteases

### *Human thrombin*

Thrombin is able to cleave GST-SHEL extensively and in a reproducible manner. Cleavage of GST-SHEL bound to glutathione agarose was performed by washing and resuspending beads in 1x thrombin cleavage buffer (50mM Tris-HCl pH8.0, 150mM NaCl, 2.5mM CaCl<sub>2</sub>) and adding human thrombin (Sigma) from 0.1 to 1% (w/v) thrombin:fusion protein at 25°C for one hour (Smith and Johnston 1988). Soluble bacterial lysates used as substrate were incubated similarly with 1x thrombin cleavage buffer, added from a 10x stock. GST (26kDa) was evident on beads by SDS-PAGE but SHEL could not be identified in the supernatant in numerous experiments. To determine whether thrombin was degrading SHEL, the entire cell lysate was subject to cleavage with increasing concentrations of thrombin. 0.01U thrombin was the lower limit for cleavage but 0.05U and greater are more effective (Figure 14). GST was clearly present. However, with 0.01U thrombin a band at

approximatley 64kDa could be discerned which may represent SHEL although this was not nearly as intense as the GST band. With higher thrombin concentrations this band disappeared and smaller fragments at 45, 34 and 22kDa were  
5 noted indicating that SHEL was indeed being cleaved by thrombin.

When increasing amounts of thrombin were added to pure SHEL, four major fragments were identified by SDS-PAGE estimated at 45, 34, 22 and 13 kDa (Figure 7) in addition  
10 to faint minor bands. The sizes of the major products were very similar to those seen with thrombin digests of GST-SHEL lysates. Even with an excess of thrombin added (1U/10µg SHEL) the smaller bands were resistant to further degradation whilst the 45kDa fragment disappeared. The  
15 pattern of degradation did not appear to be the same as the serum produced peptides. When the hirudin was added to reaction, degradation was inhibited (not shown) unlike the results seen with serum. The patterns of degradation seen with SHELδ26A was slightly different with the 22kDa  
20 fragment reduced in size to about 15 kDa consistent with the fragment not containing 26A (Figure 7).

#### *Human Plasma Kallikrein*

Like thrombin, increasing amounts of human plasma kallikrein added to SHEL resulted in specific and  
25 reproducible degradation. Three major fragments were identified by SDS-PAGE (Figure 8) estimated to be 45, 22 and 18kDa, in addition to faint minor bands. The major bands at 45kDa and 18kDa were resistant to further degradation whilst the 22kDa fragment eventually  
30 disappeared. Again, the pattern of degradation was not identical to that seen by serum. Pefabloc PK could inhibit degradation by plasma kallikrein (not shown). The pattern of degradation of SHELδ26A was somewhat different, with the 22 and 18kDa fragments missing and replaced by a 15kDa  
35 fragment (Figure 8), as was seen for serum.

*Bovine Trypsin*

Trypsin digestion of SHEL was very extensive, resulting in complete degradation with prolonged treatment. However, with dilute amounts of enzyme

5 (4x10<sup>-3</sup>U) major bands could be identified at approximately 50, 45, 40, 38, 34, 31, 22 and 18kDa, giving an overall pattern similar to serum products (Figure 9). Indeed, at low enzyme concentrations the trypsin digest profile looked virtually identical to the serum digest profile. However, 10 trypsin digestion was not easily reproducible due to the vigorous action of trypsin on SHEL. Similar results were obtained using SHELδ26A (Figure 9) except that the sizes of the smaller fragments below 34kDa were all reduced in size by approximately 4kDa and as for kallikrein and serum, the 15 22 and 18kDa fragments were replaced by a single fragment at 15kDa.

*Human Plasmin*

Using plasmin at low concentrations also gave a profile very similar to both serum and trypsin (Figure 10) 20 while at high concentration extensive degradation occurred. Major bands could be isolated using low concentration plasmin at 55, 45, 40, 34, 28, 22 and 18kDa, similar but not identical to serum digested products. Similar results were obtained using SHELδ26A (Figure 10) except that 25 smaller fragments below 34kDa were reduced by approximately 4kDa and the 22 and 18kDa fragments were replaced by 17 and 15kDa fragments.

*Human Leukocyte Elastase (HLE)*

HLE resulted in extensive degradation if left for 30 extended period. Using 1.6x10<sup>-2</sup>U numerous fragments were seen with two prominent fragments at 32 and 18kDa (Figure 11). Fragments were very difficult to isolate, however, and over digestion occurred easily. SHELδ26A produced a similar profile but with a series of fragments appearing 35 4kDa smaller (Figure 11).

#### D. Zymogram analysis of serum and proteases

To confirm the identity of proteases involved in serum digestion of SHEL, a zymogram using SHEL as a substrate was used to analyse the digestion of SHEL by serum and specific proteases (Figure 16).

The SHEL zymogram digested with serum shows a distinct cleared zone at 64kDa and a much fainter second cleared zone (Figure 16). No cleared zones corresponding to the other serum proteases were detected in the serum. It is likely that this result was due to the abundance of these proteases in serum, and the degree of molecular unfolding of the protease in the zymogram.

The second cleared zone was not seen when the serine protease inhibitor PMSF was used in the analysis. This indicates that the second cleared zone corresponds to the digestion of SHEL by kallikrein. To further confirm kallikrein activity against SHEL, serum was electrophoresed through a zymogram gel containing SHEL, the gel strip containing serum was cut into approximately 3mm strips and each gel slice incubated with 30mg of SHEL in solution. The supernatant was then analysed by SDS-PAGE. A pattern identical to kallikrein was seen from the gel slice from the zymogram corresponding to the region for kallikrein (data not shown). This confirmed kallikrein activity in serum.

The 64kDa zone identified in the zymogram analysis of SHEL digested with serum did not correspond to any of the serine proteases analysed. A 2 dimensional zymogram (first dimension isoelectric focusing gel) indicated that the isoelectric point of the enzyme which corresponds to the 64kDa zone was pI 5-5.5 (data not shown). A SwissProt database search combining pI and molecular weight indicated that the enzyme which corresponds to the 64kDa zone was likely to be either gelatinase A or B. A zymogram analysis

of gelatin digested with gelatinase A or serum demonstrated a zone of digestion corresponding to 64kDa (Figure 18). This further confirms that the 64kDa zone observed in the zymogram analysis of SHEL digested with serum corresponds to gelatinase A. A cleared zone corresponding to gelatinase B is observed at a different location in this zymogram analysis. In a zymogram analysis of gelatin digested with serum, the 64kDa zone was not observed in the presence of EDTA, or in the absence of  $\text{CaCl}_2$ , or in the presence of  $\text{ZnCl}_2$  only (Figure 17). When  $\text{CaCl}_2$  or  $\text{ZnCl}_2$  was added to the digestion, the 64kDa zone was observed (Figure 17). These results further support the contention that the enzyme which corresponds with the 64kDa zone in the zymogram analysis of SHEL digested with serum is gelatinase A. Unactivated and APMA-activated gelatinase A and gelatinase B were analysed by gelatin zymography. A 64kDa zone was observed in the gelatin zymogram digested with unactivated gelatinase A (Figure 18). This indicated that the proteolytic activity observed at 64kDa in the serum digestion of the SHEL zymogram is mediated by the unactivated form of gelatinase A. A zone corresponding to approximately 60kDa was observed in the gelatin zymogram digested with APMA-activated gelatinase A (Figure 18).

#### 25 E. Mapping of Protease-Susceptible Sites

The thrombin, kallikrein, plasmin, trypsin and serum-produced peptides indicated in Figures 5 to 11 by an arrow, were N-terminally sequenced and assigned to regions of SHEL. Peptides corresponded either to the N-terminus of SHEL or to cleavage sites C-terminally adjacent to a Lys or Arg. Sequences of peptides are shown in Table 1 and the positions of the cleavage sites are indicated diagrammatically in Figure 1.

The actual sizes, in kDa, of the fragments shown in Table 1 were determined from the amino acid sequence and

are shown in brackets. In some cases, this differed from the apparent size as determined by SDS-PAGE. Curiously, one site between residues 515 and 516 (Arg and Ala) was common to thrombin and kallikrein. In addition, this same site was also cleaved by human serum. This site was identified by sequencing to be located within 26A. The lack of a second kallikrein-produced fragment in SHEL δ26A is therefore consistent with this site being absent from this isoform. The other serum-produced bands, which were minor in comparison, were unique and appeared to consist of a mixture of peptides making the designation tentative. These peptides were the same size in both SHEL and SHELδ26A (Figure 7) indicating that they are predominantly N-terminal and that the other peptide fragment is present at a much lower level. Any significant proteolysis at these other sites in SHELδ26A should result in a 4kDa reduction in peptide size which was not evident. Due to the rampant degradation seen by both trypsin and plasmin, the smaller fragments were unable to be isolated in sufficient quantity for sequencing. However, the sizes of the fragments indicate that the 22 and 18kDa fragments of trypsin and plasmin are probably the same sequence as for kallikrein and serum. Each of the plasmin-produced bands sequenced were a mixture of the same identified sequences, not seen with any other protease or serum, and N-terminal sequence also. Since not all the plasmin and trypsin-produced peptides were able to be identified unambiguously, the likely region of cleavage for these enzymes is not shown in Figure 1.

30

#### F. Effect of S-Gal and SPS-peptide on Degradation

The major serine protease site (R/AAAGLG, SEQ ID NO:9) identified in SHEL as common to thrombin, kallikrein, serum and probably trypsin and plasmin, was produced with some flanking amino acid residues as a 14 amino acid peptide

35

(SPS-peptide). This was added to proteolytic digests of SHEL and SHEL $\delta$ 26A to assess whether this peptide could inhibit degradation by acting as an alternative site for recognition and cleavage by proteases. In addition, S-GAL, a 15 amino acid peptide corresponding to the elastin binding domain of EBP was produced to assess whether its inhibition of porcine pancreatic elastase (Hinek and Rabinovitch 1994) could be extended to other proteases with tropoelastin-degrading ability. Using a 100:1 molar excess of SPS-peptide to SHEL, more full-length SHEL was evident compared with controls using trypsin, plasmin, kallikrein and serum, judged visually by SDS-PAGE and confirmed by scanning densitometry (Figure 12). The effect was most obvious with short incubations (20 minutes) and was seen with both SHEL and SHEL $\delta$ 26A (not shown). SPS-peptide also resulted in more full-length SHEL using thrombin and HLE but to a lesser extent (Figure 12) but longer incubations with thrombin did appear to show some inhibition (Figure 12). Degradation by HLE, however, was consistently inhibited by S-GAL even with longer incubations when inhibition with SPS-peptide was no longer seen, but was not repressed altogether (Figure 12).

G. Effect of coacervation on degradation of SHEL  
SHEL, when in the coacervated state at 37°C was significantly protected from degradation by both thrombin and kallikrein (Figure 13) but not by plasmin. There was also some inhibition of HLE, trypsin and serum (Figure 13). This inhibition of degradation was not due to the presence of high concentrations of NaCl in the reaction mixture as control reactions using both lesser concentrations of SHEL that did not coacervate at 37°C (not shown) and reactions performed at lower temperatures not conducive to coacervation, did not show any difference in degradation in the presence or absence of NaCl (Figure 13).



## DISCUSSION

### Inhibition Study of Serum Degradation of SHEL.

5 Human serum was able to degrade tropoelastin in a specific  
and reproducible manner into at least five or six major  
peptide fragments. The SDS-PAGE banding pattern with serum  
is visually similar to that of Romero et al (1986).  
Various inhibitor studies confirmed the protease to be a  
10 serine protease which could be inhibited by the broad  
spectrum serine protease inhibitors Pefabloc SC and PMSF.

The lack of inhibition of serum digestion by EDTA  
suggested that metalloproteinase activity was not a major  
contributor to SHEL digestion. Indeed, EDTA appeared to  
15 enhance degradation by serum perhaps by modulating the  
action of an inhibitor of serum proteases. However, it is  
clear that metalloproteinases digest tropoelastin because  
SHEL was digested with gelatinase A and gelatinase B, as  
demonstrated by the SDS-PAGE and zymogram analysis of SHEL  
20 digested with these enzymes.

It is expected that metalloproteinases are a major  
source of proteolytic activity when tropoelastin is exposed  
to wound exudate. Indeed, a number of studies have  
demonstrated the existence of metalloproteinases in wound  
25 exudate, including MMP-2 (gelatinase A) and MMP-9  
(gelatinase B) (Tarlton et al. 1997). Accordingly, the  
invention contemplates the modification of digestion of  
tropoelastin by metalloproteinases in wound exudate, by use  
of the methods, derivatives and peptidomimetic molecules of  
30 the invention.

Thrombin did not appear to be responsible for the  
majority of serum cleavage because the degradation by serum  
was not substantially inhibited by the thrombin-specific  
inhibitor hirudin, yet controls using tropoelastin and  
35 thrombin were inhibited. Pefabloc PK, specific for

kallikrein inhibited degradation. Romero et al (1986) found that incubation of tropoelastin with kallikrein resulted in a somewhat similar profile to its incubation with serum. The present inhibitor studies with PefablocPK  
5 are therefore consistent with kallikrein and/or proteases with similar behaviour being involved. The inhibitor Pefabloc PK is, however, not completely specific for kallikrein. According to data supplied by the manufacturer, the inhibitor constant for plasma kallikrein  
10 is  $0.7\mu\text{mol/L}$  while the next most likely enzyme to be inhibited after kallikrein is trypsin with an inhibitor constant of  $1.3\mu\text{mol/L}$  followed by plasmin at  $10\mu\text{mol/L}$ . Thus, if present in excess Pefabloc PK may be inhibiting these enzymes also. However, the lowest concentration at  
15 which complete inhibition was seen ( $50\mu\text{M}$ ) was the manufacturer's recommended amount for inhibition of kallikrein in plasma samples.

#### Identification of Serum Proteolysis

20 A number of enzymes have been proposed to be responsible for the serum degradation of tropoelastin. Kallikrein (Romero et al 1986) and plasmin (McGowan et al 1996) have both been put forward as potential sources of proteolysis while a trypsin-like protease was thought to be  
25 responsible for the degradation products seen when tropoelastin was isolated from tissues (Mecham and Foster 1977). A visual comparison of SHEL degradation products from serum with the individual protease digestion products revealed only a limited similarity with thrombin and  
30 kallikrein-produced peptides while trypsin and plasmin digests appeared more similar to serum-digested peptides but only when used at low concentration. Higher concentrations and/or longer incubations completely degraded SHEL and SHEL $\delta$ 26A in contrast to long incubations  
35 with serum which did not change the pattern greatly.

Increasing amounts of thrombin easily degraded SHEL but only three major fragments were noted, unlike serum-produced peptides where 5-6 fragments were noted. Coupled with the observation from the inhibitor studies that the  
5 thrombin-specific inhibitor hirudin did not substantially reduce serum degradation, thrombin does not appear to be the major enzyme involved in serum proteolysis of SHEL. This was corroborated by sequencing of the peptide products which showed that although one of the two sites recognised  
10 by thrombin was likewise recognised by serum, the other site was not. This may have been a consequence of low thrombin concentration but this is unlikely since both sites are recognised to a similar extent (Figure 7).

Similarly, the profile of SHEL seen after kallikrein  
15 digestion only showed limited similarity to the serum produced profile i.e. the presence of a 45kDa fragment and two fragments around 20kDa. Sequencing of the peptides showed that both the sites recognised by kallikrein were recognised by serum. The other serum-produced fragments,  
20 however, were not seen as major products of kallikrein digestion although some other fragments were present at a very low level (Figure 8). Long incubations with kallikrein (overnight) failed to increase the intensity of other fragments nor increase to resemble serum digestion  
25 products (not shown), indicating that kallikrein was unlikely to be responsible for the additional serum-produced fragments. The sequencing data, effect of a kallikrein specific protease inhibitor and visual appearance of the digestion products by SDS-PAGE are all  
30 consistent with the involvement of kallikrein in serum digestion. However the presence of other serum peptide fragments not seen as major products of kallikrein digestion indicates that kallikrein alone is not responsible for the pattern seen in serum digests.

35 In contrast to thrombin and kallikrein, treatment with

plasmin and trypsin resulted in extensive degradation which could completely degrade SHEL if incubated for extended periods. The degradation profile seen with plasmin was quite unlike that seen by McGowan et al (1996) where only  
5 68 and 45kDa bands were seen suggesting that the degradation had not proceeded very far in that case. Each of these digestion profiles were more similar to serum products than either thrombin or kallikrein. By visual inspection trypsin and plasmin appeared almost identical to  
10 serum digests and each other but only at a low concentration.

There was some difficulty in the sequencing of plasmin and trypsin peptides. The plasmin-produced peptides that were sequenced were found to consist of a  
15 mixture of at least two overlapping sequences at 78/79 and 81/82 (K/AAK [aa 80-83 of SEQ ID NO:4] and K/AGA [aa 83-86 of SEQ ID NO:4]) which were the same in all of the peptide fragments sequenced. In addition, sequence from the N-terminus of SHEL was also present, which made these  
20 peptides very difficult to identify unambiguously. The presence of the same peptides throughout each fragment may be an artifact resulting from this sequence co-migrating through the entire gel with other peptides and so contaminating each subsequent peptide (J. McGovern  
25 Biomolecular Resource Facility, John Curtin School of Medical Research, Australian National University, personal communication). This may have been compounded by the low levels of peptide obtained for each fragment due to the rampant degradation by plasmin.

30 Similarly, low levels and poor resolution made it difficult to obtain sequence for the smaller trypsin peptides. However, clear sequence data were obtained for the larger fragments which all corresponded to N-terminal sequences as was the case for the same peptides from serum.  
35 This coupled with the observation that Pefabloc PK could

also inhibit trypsin in controlled reactions (not shown) and the visual similarity of peptide fragments is consistent with trypsin-like enzyme involvement with serum proteolysis but the lack of sequence data for the more  
5 informative smaller fragments means that the identification is not definitive. Similarly, the visual similarity is also consistent with plasmin involvement but this was not able to be confirmed by sequencing. Since serum proteolysis was more defined and limited than either plasmin or trypsin  
10 alone, this indicates that the presence of trypsin-like activity is probably much lower in serum and/or is more easily destroyed.

HLE digestion profile was also extensive but was different to serum, trypsin and plasmin. HLE is a serine  
15 elastase and cleaves predominantly at Val residues (Keil 1992). The difference between elastase digests of SHEL and SHEL $\delta$ 26A was more notable as most fragments, including the largest ones, were smaller in SHEL $\delta$ 26A, indicating that digestion was occurring preferentially from the N-terminal  
20 end which does not appear to be the case for the other enzymes or serum. HLE involvement in serum proteolysis is therefore unlikely.

Digestion with gelatinase A and gelatinase B (each previously treated with APMA) of SHEL revealed SDS-PAGE  
25 patterns of preferentially digested fragments. The banding pattern on SDS-PAGE for each of these proteases was similar, indicating that gelatinase A and gelatinase B were likely to cut at the same or identical sites. Thus the sequence specificities for these metalloproteinases were  
30 similar. These patterns differed from AMPA-treated serum, untreated serum and serine proteases. MMP-digestion revealed multiple bands. With prolonged incubation, tropoelastin displayed marked fragmentation.

In summary, by N-terminal sequencing, visual  
35 inspection of the degradation profiles by comparison with

that of serum and the effect of the inhibitors the results are consistent with involvement of kallikrein and/or protease(s) capable of giving a comparable cleavage pattern, in addition to at least one other enzyme probably present at a lower level. Plasmin or another trypsin-like enzyme or combination of enzymes are the most likely to be involved in the serum digestion of SHEL. Detectable thrombin and HLE activity in serum are unlikely.

#### 10 Mapping of Protease Sensitive Sites

The pattern of degradation of purified tropoelastin seen by others is similar to the sizes of peptides generated by our proteolysis experiments. The sizes seen by Mecham and Foster (1977) by their trypsin-like protease associated with tropoelastin, 57,45, 36, 24.5 and 13-14kDa are very similar to the number and sizes of peptides generated by serum and the individual serine proteases on both SHEL and SHEL $\delta$ 26A indicating that cleavage may be occurring in the same or similar places. A similar profile was seen with tropoelastin from human fibroblast cell culture (Davidson and Sephel 1987). Sequencing confirmed that one site between residues 515 and 516 was common to thrombin, kallikrein and serum and from the SDS-PAGE pattern, probably also plasmin and trypsin. All the peptides sequenced confirmed that cleavage occurred after a Lys or Arg as expected for many serine proteases (Keil 1992). However, tropoelastin contains a large number of Lys and Arg yet only a small number of these residues were actually recognised and cleaved. The fact that these same sites may be recognised by different serine proteases may be due to their accessibility and/or the surrounding amino acids.

Preferred recognition sites for kallikrein and thrombin are strongly influenced by the adjacent amino acid residues (Chang 1985; Keil 1992) but it would not have been

possible a priori to predict where preferential cleavage occurs in human tropoelastin. For example, kallikrein cleaves preferentially at Arg residues preceded by a bulky residue (Keil 1992). Both sites identified by N-terminal  
5 sequencing fall into this category, with Leu-Arg at 515 and Arg-Arg at 564. However, for example, another Arg preceded by a Leu at 571 does not appear to be recognised. The highly specific and limited proteolysis of SHEL and SHEL826A by kallikrein has allowed kallikrein treatment to  
10 be used to produce isolated C-terminal portions of tropoelastin for further study (S. Jensen and A.S. Weiss unpublished). The thrombin sites identified, however, do not fit the preferred sites for thrombin. Thrombin recognises predominantly P2-Lys/Arg-P1' where either P2 or  
15 P1' are Gly or P4-P3-Pro-Arg/Lys-P1'-P2'', where P4 and P3 are hydrophobic and P1' and P2' are non-acidic residues (Chang 1985) with Arg greatly favoured over Lys (Keil 1992). Neither SHEL nor SHEL826A contain these exact sites although the site at 152 (Lys-Pro-Lys-Ala-Pro, aa 152-156  
20 of SEQ ID NO:4) is similar to the latter recognition site of P3-Pro-Lys-P1'-P2'. Which sites are recognised and cleaved may therefore be under the influence of tropoelastin secondary structure. Trypsin cleaves predominantly at Arg and Lys with a preference for Arg,  
25 while plasmin preferentially cleaves at Lys (Keil 1992). Since there are more Lys than Arg in tropoelastin, it would be expected that these proteases would cleave more extensively as is shown to be the case.

### 30 Protection from Degradation

Experiments have demonstrated that EBP can protect tropoelastin from degradation by binding primarily to the VGVPAG [aa 453-458 of SEQ ID NO: 4] sequence of  
tropoelastin (Mecham et al 1989). A peptide S-GAL which  
35 represents the elastin binding site of EBP has been used

previously to model the interaction (Hinek and Rabinovitch 1994). It has been noted that S-GAL and EBP have some homology with the N-terminal sequence of proteases such as kallikrein, HLE and plasmin and are therefore proposed to  
5 bind to the same sequence in tropoelastin, thus acting as competitive inhibitors of the proteases (Hinek and Rabinovitch 1994; Hinek et al 1993). Hinek and Rabinovitch (1994) showed that S-GAL could significantly inhibit degradation of elastin by porcine pancreatic elastase and  
10 inferred that HLE and other serine proteases could be similarly inhibited from degrading tropoelastin. In this work, the use of S-GAL did not show any significant or consistent inhibition of proteolysis of SHEL or SHEL826A by serum, trypsin, plasmin or kallikrein although some  
15 inhibition could be seen with thrombin. However, significant and reproducible inhibition was seen with HLE but complete inhibition of degradation could not be achieved, even with the large excess of S-GAL used. The S-GAL used was HPLC-purified to remove any truncated products  
20 and it may be possible that the peptide was damaged or irreversibly denatured by this process. However, samples of S-GAL which were not HPLC purified gave similar results (not shown). The mass spectroscopy data supplied by the manufacturer indicated that the correct product was  
25 synthesised. Therefore S-GAL either did not bind to SHEL or SHEL826A very effectively or was easily displaced by the protease. Alternatively, the proteases may be binding to more than one site on tropoelastin and are therefore not effected by S-GAL.

30 In summary, S-GAL showed partial inhibition of tropoelastin degradation by HLE and thrombin but inhibition was not as thorough as seen by Hinek and Rabinovitch (1994) using porcine pancreatic elastase. More extensive inhibition of other proteases and serum could not  
35 be shown consistently. N-terminal sequencing data revealed



one site in SHEL which was commonly recognised by thrombin, kallikrein, serum and probably trypsin and plasmin. This site and its flanking amino acids was synthesised and this SPS-peptide added to the proteolytic digests of SHEL and  
5 SHEL $\delta$ 26A. This peptide was not expected to bind to tropoelastin but simply act as a competitor by being recognised by the protease thus slowing degradation of SHEL and SHEL $\delta$ 26A. There was reproducible evidence of protection from degradation of SHEL and SHEL $\delta$ 26A by the  
10 presence of SPS-peptide. The amount of full-length protein was greater in the presence of SPS-peptide than in the presence of S-GAL or control digestions and was similar for both isoforms. This was most notable in the presence of low enzyme concentrations or shorter incubations and was  
15 most obvious with trypsin, plasmin, kallikrein and serum although protection from the other proteases was noted although at a reduced level. This indicates that each of the proteases and serum could recognise this peptide to some extent and therefore this is a potential inhibitor of  
20 proteolysis of tropoelastin.

There is no direct evidence that SPS-peptide is cleaved by any protease. However, the presence of a similar amount of a different peptide (S-GAL) did not exert the same effect. Thus the effect of SPS-peptide is  
25 probably not simply due to the non-specific presence of a peptide in the reaction. SPS-peptide is therefore likely to be interacting directly with the proteases (or tropoelastin) to exert its effect. SPS-peptide may allow full-length tropoelastin to persist longer in the presence  
30 of proteases, including human serum.

In summary, the inhibition of degradation of SHEL and SHEL $\delta$ 26A by S-GAL was only noted significantly with HLE but more extensive protection could not be shown. However a reproducible inhibition was seen in the presence of SPS-  
35 peptide with each protease and serum, and was most notable

with trypsin, kallikrein and serum. This peptide provides an alternative site for interaction with proteases and results in the persistence of full-length tropoelastin for longer periods.

5

#### Proteolysis of Coacervated Tropoelastin

Coacervation of SHEL and SHEL $\delta$ 26A at 37°C resulted in significant protection from proteolysis by kallikrein and thrombin and to a lesser extent by HLE, trypsin and serum.

10 No protection was seen from attack by plasmin. The presence of 150mM NaCl did not appear to cause the inhibition since the same reactions performed under conditions not conducive to coacervation (16°C) were digested to a similar extent in the presence or absence of  
15 NaCl. Although it is possible that a simple change in conformation at 37°C could result in altered proteolytic susceptibility, this is unlikely since coacervated and non-coacervated SHEL both at 37°C were digested at different rates. The inhibition of proteolysis is  
20 therefore probably due to steric restriction in the coacervate. Of the enzymes tested, the activity of kallikrein was most significantly inhibited by coacervation. From the N-terminal sequencing results, kallikrein predominantly recognises only two sites in SHEL,  
25 both of which are in close proximity, and only one in SHEL $\delta$ 26A. The coacervation of tropoelastin appears to mask these sites making them less accessible to kallikrein. With thrombin, the inhibition was not as complete as with kallikrein. Thrombin recognises predominantly two sites in  
30 SHEL also but these are more distant from each other. The process of coacervation may mask these sites but if either site is slightly more accessible proteolysis would result and consequently allow easier access to the second site. Other proteases (HLE, trypsin, plasmin) and also serum  
35 recognise and cleave at many more sites within SHEL making

efficient masking of all sites by coacervation unlikely and resulting in some sites remaining available for recognition and proteolysis to occur. Thus, these proteases are not as significantly inhibited by coacervation. These results  
5 indicate that in the extracellular matrix, coacervation of tropoelastin may serve an additional role to those already proposed by providing to a certain extent, protection from proteolysis including that caused by human serum. These results could be extended to the nascent elastic fibre  
10 where newly laid tropoelastin in the coacervate would be largely protected from extracellular proteases before cross-linking makes this protection essentially permanent.

Possible consequences of serum degradation of tropoelastin  
15 It is clear from these results and those of others that serum contains factors capable of degrading tropoelastin. A number of serine proteases present in human blood have been shown here to be able to degrade tropoelastin specifically and reproducibly. Thus  
20 tropoelastin when secreted by cells into the extracellular matrix is vulnerable to extensive degradation prior to being insolubilised by lysyl oxidase and cross-linked. This is especially significant in blood vessels where damaged vessels may contain a number of these proteases  
25 during normal blood coagulation. Any tropoelastin secreted at this time and not protected, for example by EBP or by coacervation, would be fragmented. These results suggest that coacervation may indeed provide some protection from digestion as seen with the inhibition of degradation of  
30 coacervated SHEL (Figure 13). However, protection is by no means complete. It has previously been suggested that tropoelastin may be under negative feedback autoregulation and upon accumulation in the extracellular matrix may inhibit the production of elastin mRNA (Foster and Curtiss  
35 1990). Elastin peptides produced by proteases such as

elastase have been shown to produce negative feedback inhibition when added to undamaged fibroblast cultures while stimulating tropoelastin production in protease damaged cultures (Foster et al 1990). It has been  
5 suggested that serine protease mediated proteolysis of tropoelastin may be an important modulator of tropoelastin production and that plasmin may be involved in this process (McGowan et al 1996). Our results are consistent with this proposal although the specific enzyme(s) proposed  
10 differ slightly.

It is interesting to note that most of the cleavages identified in serum occur in the C-terminal half of the tropoelastin molecule and that most of the larger fragments were from the N-terminus (Figure 1, Table 1). Thus the  
15 action of proteases in serum on tropoelastin serves to degrade the C-terminal portion leaving a large N-terminal segment. These shortened molecules may not be incorporated into newly synthesised or growing elastic fibers due to the absence of the highly conserved C-terminus which is shown  
20 to be responsible for binding with microfibrillar proteins (Brown-Ausburger et al 1996; 1994). This is analogous to the case in supra-avalvular aortic stenosis, where an elastin gene truncation results in tropoelastin missing the C-terminus with the result of severe aortic disease (Ewart et  
25 al 1994). Similarly, in fetal lamb ductus arteriosus a truncated tropoelastin missing the C terminus is not incorporated into the elastic fibre (Hinek and Rabinovitch 1993). The action of serum on human tropoelastin therefore results in tropoelastin molecules which may not be rendered  
30 insoluble and may persist in the extracellular matrix. Any fibers cross-linked may be aberrant due to improper alignment, resulting in a loss of elastic properties and strength. The persistence of soluble peptides may serve to inhibit further tropoelastin production by negative  
35 feedback inhibition (Foster and Curtiss 1990). At the same

time peptides are chemotactic, as demonstrated by several studies (Bisaccia et al 1994; Grosso and Scott 1993) and may serve to recruit tissue repairing cells to the site of injury, accelerating repair of the wound. Chemotactic  
5 peptides may differ in efficacy from for example SHEL and SHELδ26A.

#### Conclusion

Human serum was shown to be capable of degrading SHEL and SHELδ26A into a number of discrete fragments. This  
10 activity was confirmed to be from a serine protease and the regions of susceptibility to serum were precisely mapped by N-terminal sequencing. A number of other serine proteases were shown to be capable of degrading SHEL and SHELδ26A. From the pattern of degradation, use of selective  
15 inhibitors and N-terminal sequencing the protease responsible for serum degradation was consistent with a trypsin-like protease but kallikrein or kallikrein -like behaviour is also a likely contributor. Significant or consistent inhibition of proteolysis did not take place  
20 using S-GAL except with thrombin and HLE but reproducible inhibition was provided by SPS-peptide. However, the process of coacervation was shown to provide the most significant protection against proteolysis including by serum and was most notable for proteases which cleaved a  
25 limited number of sites.

Cleavage of SHEL and SHELδ26A with metalloproteinases to generate reproducible patterns with apparently preferred cleavage sites has also been demonstrated.

#### 30 INDUSTRIAL APPLICATION

The derivatives and expression products of the invention are of use in *inter alia* the medical, pharmaceutical, veterinary and cosmetic fields as tissue bulking agents, and agents for cellular chemotaxis,  
35 proliferation and growth inhibition, in particular of

smooth muscle cells, epithelial cells, endothelial cells, fibroblasts, osteocytes, chondrocytes and platelets.

TABLE 1: N-terminal Sequences of Protease-Produced Tropoelastin Peptides

	Size (kDa)*	Sequence†	[SEQ ID NO:]	Position
thrombin	45	GGVPGAIPG	<u>aa 3-11 of SEQ ID NO: 4</u>	
	34	K/APGVGGAF	<u>aa154-162 of SEQ ID NO:4</u>	152/153
	22(19)	R/AAAGLG	<u>aa 517-523 of SEQ ID NO:4</u>	515/516
kallikrein	45	GGVPGAIPG	<u>aa 3-11 of SEQ ID NO: 4</u>	
	22(19)	R/AAAGLG	<u>aa 517-523 of SEQ ID NO:4</u>	515/516
	18(15)	R/SLSPELREGD	<u>aa 566-523 of SEQ ID NO:4</u>	564/565
Trypsin	55	GGVPGAIPG	<u>aa 3-11 of SEQ ID NO: 4</u>	
	45	GGVPGAIPG	<u>aa 3-11 of SEQ ID NO: 4</u>	
	40	GGVPGAIPG	<u>aa 3-11 of SEQ ID NO: 4</u>	
	34	GGVPGAIPG	<u>aa 3-11 of SEQ ID NO: 4</u>	
Plasmin	55	GGVPGAIP	<u>aa 3-11 of SEQ ID NO: 4</u>	
	45	K/AAKAGAGL +	<u>aa80-88 of SEQ ID NO:4</u>	78/79
	40	GGVPGAIP	<u>aa 3-11 of SEQ ID NO: 4</u>	78/79 +
	34	K/AAKAGAGL +	<u>aa80-88 of SEQ ID NO:4</u>	81/82
	28	K/AGAGLGGV	<u>aa83-91 of SEQ ID NO:4</u>	78/79 +
		K/AAKAGAGL +	<u>aa80-88 of SEQ ID NO:4</u>	81/82
		K/AGAGLGGV	<u>aa83-91 of SEQ ID NO:4</u>	78/79 +
		K/AAKAGAGL +	<u>SEQ ID NO:102</u>	81/82
gelatinase B	10(12)	A/LAAKAAKYGAA	<u>SEQ ID NO:103</u>	593/594
Serum	50	GGVPGAIPGGVP	<u>aa 3-14 of SEQ ID NO:4</u>	
	45	GGVPGAIPGG	<u>aa 3-12 of SEQ ID NO:4</u>	
	34	GGVPGAIPGGVP	<u>aa 3-14 of SEQ ID NO:4</u>	
	28 (25)	GGVPGAIPG +	<u>aa 3-11 of SEQ ID NO:4</u>	441/442
	27	K/AAQFGLVPGV(?)‡	<u>SEQ ID NO:104</u>	
	25 (20)	GGVPGAIPGGVPGGFYPG	<u>SEQ ID NO: 105</u>	503/504
	22 (19)	GGVPGAIPG +	<u>aa 3-11 of SEQ ID NO:4</u>	515/516
	18 (15)	K/SAKVAAKAQ(?)	<u>505-515 of SEQ ID NO:4</u>	564/565
	13	R/AAAGLG	<u>aa 517-523 of SEQ ID NO:4</u>	
		R/SLSPELRE	<u>aa 566-574 of SEQ ID NO:4</u>	
		GGVPGAIP	<u>aa 3-10 of SEQ ID NO:4</u>	
<p>* Size of fragments are calculated from SDS-PAGE and are approximate. Sizes in brackets are the sizes determined from the position of the cleavage determined by N-terminal sequencing.</p> <p>† A slash (/) indicates an internal cleavage site adjacent to an R or K residue (bold). N-terminal sequence of residues to the right of these sites was obtained allowing the precise location of the cleavage site to be allocated and the exact size of the fragment to be calculated.</p> <p>‡ A question mark (?) indicates that this designation is tentative. The peptide is likely to be present at a very low level and as a mixture with other peptides.</p>				

REFERENCES

1. Indik Z, Yeh H, Ornstein-Goldstein N, Sheppard P, Anderson N, Rosenbloom JC, Peltonen L and Rosenbloom J  
5 (1987) *PNAS (USA)* 84 5680-5684
2. Indik Z, Abrams W.R., Kucich U, Gibson C.W., Mecham R.P. and Rosenbloom J (1990) *Arch. Biochem Biophys* 280 80-86
3. Oliver L, Luvalle PA, Davidson J.M., Rosenbloom J,  
10 Mathew C.G., Betser A.J. and Boyd C.D. (1987) *Collagen Rel Res* 7 77-89
4. Sambrook J., Fritsch E.F., and Maniatis T. (1989) *Molecular Cloning: a laboratory Manual, second edition Cold Spring Harbor Laboratory Press, Cold Spring Harbor , New York*  
15
5. Bressan G.M., Argos P. and Stanley K.K. (1987) *Biochemistry* 26 1497-11503
6. Raju K. and Anwar R.A. (1987) *J. Biol Chem* 262 5755-5762
- 20 7. Pierce R.A., Alatawi A, Deak S.B. & Boyd C.D. (1992) *Genomics* 12 651-658
8. Lipman and Pearson (1985) *Science* 227,1435.
9. Bedell-Hogan, D., Trackman, P., Abrams, W., Rosenbloom, J. and Kagan H. (1993) *J. Biol. Chem.* 268,  
25 10345-10350
10. Studier, F. W., Rosenberg, A. H., Dunn, J. J. and Dubendorff, J. W. (1990) *Methods Enzymol.* 185, 60-89
11. Gough, J., and Murray, N. (1983) *J. Mol. Biol.* 166, 1-19
- 30 12. Bullock, W. O., Fernandez, J. M. and Short, J. M. (1987) *BioTechniques* 5, 376-379
13. Bisaccia F, Catiglione Morelli M A, De Biasi M, Traniello S, and Tarnburro A M. (1994) *Int. J. Peptide Protein Res*, 44: 332-341
- 35 14. Chang J Y (1985) *Eur. J. Biochem.* 151: 217-224

15. Grosso L E and Scott M (1993)  
*Arch. Biochem. Biophys.* 305: 401-404
16. Franzblau C, Pratt C A, Faris B, Colannino N M, Offner  
G D, Mogayzel P J and Troxler R F (1989)  
5 *J. Biol. Chem.* 264: 15115-15119
17. Hayashi A, Wachi M and Tajima S (1995)  
*Biochim. Biophys. Acta* 1244: 325-330
18. Keil B (1992) *Specificity of Proteolysis*
19. Kobayashi J, Wigle D, Childs T, Zhu, L, Keeley F W and  
10 Rabinovitch M (1994) *J. Cell. Physiol.* 160: 121-131
20. Martin S L, Vrhovski B and Weiss A S (1995)  
*Gene* 154, 159-166
21. Mecham R P, Foster J A and Franzblau C (1976)  
*Biochim. Biophys. Acta.* 446: 245-2,54
- 15 22. Mecham R P and Foster J A (1977)  
*Biochem.* 16: 3825-3831.
23. Mecham R P, Foster J A and Franzblau C (1977)  
*Adv. Expt. Med. Biol.* 79: 209-216
24. Rich C B and Foster J A (1984)  
20 *Biochem. J.* 217: 581-584
25. Romero N, Tinker D, Hyde D and Rucker R B (1986)  
*Arch. Biochem. Biophys.* 244: 161-168
26. Rucker R B (1982) *Meth. Enzym.* 82: 650-657
27. Sandberg L B and Wolt T B (1982) *Meth. Enzym.* 82: 657-  
25 665
28. Torres A R, Alvarez V L, Sandberg L B and Gray W R  
(1977) *Adv. Expt. Med. Biol.* 79: 267-276
29. McGowan S E, Lui R, Harvey C S and Jaeckel E C (1996)  
*Am. J. Physiol.* 270: L376-1385.
- 30 30. Heim R A, Pierce R A, Deak S B, Riley D J, Boyd C D  
and Stolle C A, (1991) *Matrix* 11: 359-366.
31. Yeh H, Ornstein-Goldstein N, Indik Z, Sheppard P,  
Anderson N, Rosenbloom J C, Cicila G, Yoon K and Rosenbloom  
J (1987) *Collagen Rel. Res.* 7: 235-237
- 35 32. Hinek A and Rabinovitch M (1994) *J. Cell Biol.* 126:



563-574.

33. Davidson J M and Sephel G C (1987) *Meth. Enzym.* 144: 214-232.

34. Mecham R P, Hinek A, Entwistle R, Wrenn D S, Griffin G  
5 L and Senior R M (1989) *Biochem.* 28: 3716-3722.

35. Foster, J. A. and Curtiss S. W. (1990) *Am. J. Physio.*  
259: L13-L23.

36. Ewart A K, Morris C A, Atkinson D, Jin W, Sternes K,  
Spallone P, Stock A D, Leppert M and Keating M T (1993)  
10 *Nature Gen.* 5: 11-16.

37. Smith D B and Johnson K S (1988) *Gene* 67: 31-40.

38. Tarlton J F, Vickery C J, Leaper D J and Bailey A J  
(1997) *B. J. Derm.* 137: 506-516.